As filed with the Securities and Exchange Commission on September 10, 2021

Registration No. 333-258825

As filed with the Securities and Exchange Commission on September 29, 2011Registration No. 333-175283
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

AMENDMENT NO. 2 TO

Pre-Effective Amendment No. 1

to

FORM S-3

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933


ATRINSIC, INC.

Protagenic Therapeutics, Inc.

(Exact nameName of registrantRegistrant as specifiedSpecified in its charter)

Its Charter)

Delaware06-1390025
(State or jurisdictionOther Jurisdiction of
Incorporation or Organization)
(I.R.S Employer
incorporation or organization)(I.R.S. Employer
Identification Number)

469 7149 Fifth Avenue

th Avenue, 10th Floor

New York, NY 10018
(212) 716-1977
(Address, including zip code, and telephone number, including area code,
of registrant’s principal executive offices)
Stuart Goldfarb, Chief Executive Officer
Atrinsic, Inc.
469 7th Avenue, 10th Floor
New York NY 10018
(212) 716-1977
 (Name, address, including zip code, and telephone number, including
area code, of agent for service)
Copy to:
Scott Galer, Esq.
Stubbs Alderton & Markiles, LLP
10010

15260 Ventura Boulevard, 20212-994-8200

th Floor

Sherman Oaks, California 91403
(818) 444-4500
(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)

Garo Armen

Executive Chairman

Protagenic Therapeutics, Inc.

149 Fifth Avenue

New York, New York 10010

212-994-8200

(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent forFor Service)

Copies to:

Dean M. Colucci, Esq.

Michelle Geller, Esq.

Kelly R. Carr, Esq.

Duane Morris LLP

1540 Broadway

New York, New York 10036

Telephone: (973) 424-2020

Approximate date of commencement of proposed sale to the public: From time to time after the effective date of this registration statement.

If the only securities being registered on this formForm are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ¨

[  ]

If any of the securities being registered on this formForm are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. x[X]

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨

[  ]

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨

[  ]

If this formForm is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box: ¨

box. [  ]

If this formForm is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box: ¨

box. [  ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”filer,” “smaller reporting company” and “smaller reporting“emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer¨
[  ]
Accelerated filer¨
Non-accelerated filer ¨
Smaller reporting[  ]
  (Do not check if a smaller
Non-accelerated filer[X]Smaller reporting company)company
[X]
Emerging growth companyx[  ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. [  ]

CALCULATION OF REGISTRATION FEE

Title of Each Class
of Securities
To Be Registered
 
Amount To Be
Registered (1)
  
Proposed
Maximum
Offering Price
Per Unit (2)(3)
  
Proposed
Maximum
Aggregate
Offering Price (2)(3)
  
Amount
Of
Registration
Fee (4)
 
Common Stock, par value $.01 per share  5,963,857  $3.03  $18,070,486.71  $2,097.99 

Title of Each Class of

Securities to be Registered

 

Amount

to be Registered(1)

  Proposed Maximum Offering Price Per Security(2)  Proposed Maximum Aggregate Offering Price  Amount of Registration Fee 
Common Stock, $0.0001 par value per share  7,221,607(3) $1.93  $13,937,701.51(3) $1,520.60(4)

(1)In the event of a stock split, stock dividend, or other similar transaction involving the Registrant’s common stock, in order to prevent dilution, the number of shares registered shall automatically be increased to cover the additional shares in accordance with Rule 416(a) under the Securities Act.
(2)
Estimated solely for the purpose of calculating the registration fee pursuantPursuant to Rule 457(c)416 under the Securities Act of 1933 using(the “Securities Act”), the Registrant is also registering hereunder an indeterminate number of additional shares of common stock that shall be issuable to prevent dilution resulting from stock splits, stock dividends or similar transactions.

(2)Estimated in accordance with Rule 457(c) solely for purposes of calculating the registration fee. The maximum price per Security and the maximum aggregate offering price are based on the average of the high$2.00 (high) and low$1.86 (low) sale price of the Registrant’s common stock as reported on the NASDAQ Capital MarketNasdaq on September 23, 2011.08/12/2021, which date is within five business days prior to filing this Registration Statement.
(3)The proposed maximum offering price per unit will be determined from time to time byReflects the selling stockholders in connection with, and at the timeregistration of the issuance by the selling stockholders420,000 additional shares. 6,801,607 shares of the securities registered hereunder.common stock were previously registered.
(4)A registration fee of $2,366.71was paid on June 30, 2011 upon the initial filing of the Registration Statement, as amended by Amendment No. 1 to Registration Statement filed on September 1, 2011, and as further amended by this Amendment No. 2 to Registration Statement.$1432.17 was previously paid.

The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.

 

EXPLANATORY NOTE

Protagenic Therapeutics, Inc. is filing this pre-effective amendment to the Registration Statement on Form S-3 (File No. 333-258825) in order to update the sections entitled “Selling Stockholders” and “Information Incorporated by Reference” of the Registration Statement.



Subject

The information in this prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to Completion, Datedsell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

SUBJECT TO COMPLETION, DATED September 29, 2011

ATRINSIC, INC.
5,963,857 10, 2021

PROSPECTUS

7,221,607 Shares

of Common Stock

Offered by Selling Stockholders

This prospectus relates to the offer and sale of 7,221,607 shares of common stock par value $0.0001 per share for the account of the selling stockholders named in this prospectus. All of these shares of common stock are being sold by the selling stockholders named in this prospectus, or their respective pledgees, donees, assignees, transferees and successors-in-interest.

The shares of common stock described in this prospectus or in any supplement to this prospectus may be sold from time to time pursuant to this prospectus by the selling stockholders in ordinary brokerage transactions, in transactions in which brokers solicit purchases, in negotiated transactions, or in a combination of upsuch methods of sale, at fixed prices, at market prices prevailing at the time of sale, at prices related to 5,963,857such prevailing market prices, at varying prices determined at the time of sale, or at negotiated prices. See “Selling Stockholders” and “Plan of Distribution.” We cannot predict when or in what amounts a selling stockholder may sell any of the shares offered by this prospectus.

We are not selling any shares of our common stock, that are held by the shareholders named in the “Selling Stockholders” section of this prospectus.  The prices at which the selling stockholders may sell the shares in this offering will be determined by the prevailing market price for the shares or in negotiated transactions.  Weand we will not receive any of the proceeds from the sale of shares by the shares. We will bear all expenses of registration incurred in connection with this offering.selling stockholders. The selling stockholders whosewill pay all brokerage fees and commissions and similar sale-related expenses. We are only paying expenses relating to the registration of the shares are being registered will bear all sellingwith the U.S. Securities and other expenses.

Exchange Commission.

A supplement to this prospectus may add, update or change information contained in this prospectus. You should read this prospectus and any prospectus supplement, together with the documents we incorporate by reference, carefully before you invest.

Our common stock is quotedlisted on the NASDAQNasdaq Capital Market under the symbol “ATRN.“PTIX” and our Warrants are listed on the Nasdaq Capital Market under the symbol “PTIXW.” On September 27, 2011,9, 2021, the last reported sales price of thefor our common stock on the NASDAQ Capital Market was $2.65$1.97 per share.

For

An investment in our securities involves a discussionhigh degree of important factors that you should consider before purchasingrisk. See the shares of common stock, see “Risk Factors” beginningsections entitled “Risk Factors” in our most recent Annual Report on page 9 of this prospectus.


Form 10-K and in any Quarterly Report on Form 10-Q, as well as in any prospectus supplement related to these specific offerings.

This prospectus may not be used to offer or sell any securities unless accompanied by a prospectus supplement.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracydetermined if this prospectus is truthful or adequacy of this prospectus.complete. Any representation to the contrary is a criminal offense.


The date of this prospectus is [●]September 10, 2021, 2011


2


TABLE OF CONTENTS
 

TABLE OF CONTENTS

ABOUT THIS PROSPECTUS5
PROSPECTUS SUMMARY6
RISK FACTORS7
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS7
DIVIDEND POLICY8
USE OF PROCEEDS8
SELLING STOCKHOLDERS8
DESCRIPTION OF CAPITAL STOCK11
PLAN OF DISTRIBUTION13
LEGAL MATTERS16
EXPERTS16
WHERE YOU CAN FIND MORE INFORMATION16
LIMITATION ON LIABILITY AND DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES16
INFORMATION INCORPORATED BY REFERENCE17

4

ABOUT THIS PROSPECTUS

This prospectus is part of a registration statement on Form S-3 that we have filed with the U.S. Securities and Exchange Commission (the “SEC”) utilizing a “shelf” registration process. Under this shelf registration process, the selling stockholders named in this prospectus or any supplement to this prospectus may sell the securities described in this prospectus in one or more offerings. This prospectus provides you with a general description of the securities. The selling stockholders are required to provide you with this prospectus and, in certain cases, a prospectus supplement containing specific information about the selling stockholders and the terms upon which the securities are being offered. A prospectus supplement may also add to, update or change the information contained in this prospectus. If there is any inconsistency between the information in this prospectus and any applicable prospectus supplement, you should rely on the information in the applicable prospectus supplement. Please carefully read this prospectus, any applicable prospectus supplement and any free writing prospectus together with the additional information described under the headings “Where You Can Find More Information” and “Information Incorporated by Reference.”

We and the selling stockholders have not authorized anyone to provide any information or to make any representations other than those contained in this prospectus or incorporated by reference in this prospectus. We and the selling stockholders take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. You should not assume that the information in this prospectus is accurate as of any date other than the date on the cover page of this prospectus or that any information we have incorporated by reference is accurate as of any date other than the date of the documents incorporated by reference. Our business, financial condition, results of operations and prospects may have changed since those dates.

In this prospectus, unless otherwise indicated, “our company,” “Protagenic,” “we,” “us” or “our” refer to Protagenic Therapeutics, Inc., a Delaware corporation, and its consolidated subsidiaries.

5

PROSPECTUS SUMMARY

This prospectus summary highlights certain information about our company and other information contained elsewhere in this prospectus or in documents incorporated by reference. This summary does not contain all of the information that you should consider before making an investment decision. You should carefully read the entire prospectus, any prospectus supplement, including the section entitled “Risk Factors” and the documents incorporated by reference into this prospectus, before making an investment decision.

The Company

We are a biopharmaceutical corporation specializing in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders utilizing synthetic forms of endogenous brain signaling peptides that can dampen overactive stress responses.

The mechanism by which we will target these stress-related disorders is based on over 15 years of work elucidating the role of Teneurin Carboxy-terminal Associated Peptide (“TCAP”), which has been found to have a central role in maintaining healthy brain signaling. TCAP is an endogenous counterbalance to the negative effects of stress and its criticality is underscored by a high degree of evolutionarily preservation. TCAP signaling counteracts the effects of Corticotropin Releasing Factor on the Hypothalamic-Pituitary-Adrenal axis, thus reducing the stress hormone cortisol. We intend to bring novel forms of TCAP into human clinical development as a treatment for stress-related neuropsychiatric disorders. Our lead compound – PT00114 – is a 41-residue peptide synthetic form of TCAP that can be administered subcutaneously, sublingually, or intra-nasally. In addition, we have a portfolio of earlier stage neuropeptides targeting the TCAP pathway that are in preclinical evaluation.

Our strategy is to develop TCAP neuropeptide-based drug candidates, beginning with PT00114, in stress-related indications, including, but not limited to: treatment resistant depression (“TRD”), which is a subgroup of major depressive disorder (“MDD”); addiction, recidivism, or substance use disorder (“SUD”); anxiety, including generalized anxiety disorder (“GAD”), and post-traumatic stress disorder (“PTSD”).

Corporate Information

We are a Delaware corporation with one subsidiary, Protagenic Therapeutics Canada (2006) Inc., a corporation formed in 2006 under the laws of the Province of Ontario, Canada. Our principal offices are located at 149 Fifth Avenue, New York, New York 10010. Our telephone number is (212) 994-8200. The inclusion of our website address does not include or incorporate by reference into this prospectus supplement or the accompanying prospectus any information on, or accessible through, our website. Our annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, together with amendments to these reports, are available on the “Investor Relations” section of our website, free of charge, as soon as reasonably practicable after such material is electronically filed with, or furnished to, the U.S. Securities and Exchange Commission (“SEC”).

This Offering

We are registering for resale by the selling stockholders named herein an aggregate shares of our Common Stock as described below.

Issuer: PageProtagenic Therapeutics, Inc
   
Prospectus SummarySecurities being offered: 47,221,607 shares of our Common Stock
Risk Factors 10
Forward-looking Statements22 
Use of Proceedsproceeds: 22We will not receive any of the proceeds from the sale or other disposition of shares of our Common Stock by the selling stockholders. The selling stockholders will bear all selling and other expenses incurred in connection with the sale or other disposition by them of the shares covered hereby.
 
Selling StockholdersMarket for common stock: 23Our Common Stock is listed on the Nasdaq Capital Market under the symbol “PTIX.” On September 9, 2021, the closing price of our Common Stock was $1.97 per share.
 
Plan of DistributionRisk factors: 32See “Risk Factors” beginning on page for risks you should consider before investing in our shares.

Legal Matters34
Experts34
Where You Can Find More Information35
Information Incorporated by Reference356

You

RISK FACTORS

Investing in our securities involves risk. The prospectus supplement applicable to a particular offering of securities will contain a discussion of the risks applicable to an investment in Protagenic and to the particular types of securities that we are offering under that prospectus supplement. Before making an investment decision, you should rely onlycarefully consider the risks described under “Risk Factors” in the applicable prospectus supplement and the risks described in our most recent Annual Report on Form 10-K for the year ended December 31, 2020, as amended from time to time, which is incorporated herein by reference, or any updates in our Quarterly Reports on Form 10-Q, together with all of the other information appearing in or incorporated by reference into this prospectus and any applicable prospectus supplement, in light of your particular investment objectives and financial circumstances. Our business, financial condition or results of operations could be materially adversely affected by any of these risks. The trading price of our securities could decline due to any of these risks, and you may lose all or part of your investment.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This prospectus contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, or Securities Act, and Section 21E of the Securities Exchange Act of 1934, or Exchange Act. Forward-looking statements reflect the current view about future events. When used in this prospectus, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this prospectus relating to our business strategy, our future operating results and liquidity and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward–looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any supplementof these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, the results of clinical trials and the documentsregulatory approval process; our ability to raise capital to fund continuing operations; market acceptance of any products that may be approved for commercialization; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize new and improved products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors (including the risks contained in the section entitled “Risk Factors” of the applicable prospectus supplement) relating to our industry, our operations and results of operations. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.

Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we have incorporated by reference.  do not intend to update any of the forward-looking statements to conform these statements to actual results.

7

DIVIDEND POLICY

We have not authorized anyone to provide information that is different from that contained in this prospectus.  The information contained in this prospectus,never paid any supplement and any document incorporated by reference is accurate only as of the date of such document, regardless of the time of delivery of this prospectus or of any sale of our common stock.


3



PROSPECTUS SUMMARY
This summary highlights selected information incorporated by reference or contained in greater detail elsewhere in this prospectus. This summary does not contain all the information you should consider before investing incash dividends on our common stock. You should readWe anticipate that we will retain funds and future earnings to support operations and to finance the entire prospectusgrowth and the documents incorporated by reference carefully before making an investment decision, including “Risk Factors” and the consolidated financial statements and the related notes incorporated by reference herein. References in this prospectusdevelopment of our business. Therefore, we do not expect to “Atrinsic” “ATRN,” “we,” “our” and “us” refer to Atrinsic, Inc. and our consolidated subsidiaries.
Overview
Atrinsic, Inc. is a marketer of direct-to-consumer subscription products and an Internet search-marketing agency. We sell entertainment and lifestyle subscription products directly to consumers, which we market through the Internet. We also sell Internet marketing services to our corporate and advertising clients. We have developed our marketing media network, consisting of web sites, proprietary content and licensed media, to attract consumers, corporate partners and advertisers. We believe our marketing media network and proprietary technology allows us to cost-effectively acquire consumers for our products and for our corporate partners and advertisers.
Our business is focused on two key areas:

·Direct-to-consumer subscriptions, built around the Kazaa brand, and

·Search and affiliate marketing, built around the Atrinsic Interactive brand.

Our direct-to-consumer subscription business is built around a recurring-revenue business model.  We are focused on digital musicpay cash dividends in the rapidly growing mobile space, and our leadforeseeable future following this offering, Kazaa, is a recognizable brand in this market.  We also provide alternative billing capabilities, allowing our subscribersif at all. Any future determination to utilize payment methods other than just credit cards, to purchase our services.  Our core strategic focus for Kazaa and our direct-to-consumer subscription business is to build and sustain a large and profitable subscriber base and a growing and engaged audience and to deliver entertainment content to our customers anywhere, anytime and on any device, in a manner our customers choose.

Atrinsic Interactive, our affiliate network and search marketing agency, is a top ten search agency according to Advertising Age (2010) and a top-tier affiliate network.  We offer advertisers an integrated service offering across paid search, or search engine marketing (“SEM”), search engine optimization (“SEO”), display advertising, affiliate marketing, as well as offering business intelligence and brand protection services to our clients.  We work with all types and sizes of advertisers on a performance basis to assist them in acquiring customers at an attractive return on investment.  Our core strategic focus for Atrinsic Interactive is to build a leading independent search marketing agency and a top-five affiliate network.
In February 2008, New Motion, Inc., a subscription-based mobile content company which was originally incorporated  in 1994 under the laws of the state of Delaware under the original name, The Millbrook Press, Inc., merged with Traffix, Inc., an Internet marketing company.  Pursuant to the merger, Traffix became our wholly owned subsidiary and in June 2009, after approval by our stockholders, we changed our name from New Motion, Inc. to Atrinsic, Inc. and also changed our ticker symbol from “NWMO” to “ATRN.”

4


Since the merger with Traffix, we have engaged in several other transactions, including our purchase of the Ringtone.com assets in June 2008 for approximately $8.8 million in cash and notes.  This acquisition gave us a prominent domain from which to market our mobile content services. In addition, in October 2008, we acquired a 36% minority interest in The Billing Resource, LLC (“TBR”), initially contributing $2.2 million to its formation.  TBR is an aggregator of fixed line telephone billing, providing its customers with the ability to charge end user customer’s telephone bills for subscription services they deliver.

On July 31, 2009, the Company entered into an Asset Purchase Agreement with ShopIt.com pursuant to which the Company acquired certain net assets from ShopIt.com, including but not limited to software, trademarks and certain domain names. In consideration for the assets, the Companypay dividends will be at the closing cancelled $1.8 million in aggregate principal amountdiscretion of indebtedness owed by ShopIt to the Company, paid to ShopIt $450,000our board of directors and issued 95,000 shareswill depend on our financial condition, results of the Company’s common stock.  The Company is not currently using the Shop-It.com assets.

On March 26, 2010, we entered into a Marketing Services Agreement (the “Marketing Agreement”)operations, capital requirements and a Master Services Agreement (the “Services Agreement”) with Brilliant Digital, Inc. (“Brilliant Digital”) effective asother factors that our board of July 1, 2009 (collectively, the “Agreements”), relating to the operation and marketing of the Kazaa digital music service.  The Agreements govern the operation of Brilliant Digital’s Kazaa digital music service, which is jointly operated by us and Brilliant Digital. Under the Marketing Services Agreement, we are responsible for marketing, promotional, and advertising services for the Kazaa business. Pursuant to the Master Services Agreement, we provide services related to the operation of the Kazaa business, including billing and collection services and the operation of the Kazaa online storefront.  Brilliant Digital is obligated to provide certain other services with respect to the Kazaa business, including licensing the intellectual property underlying the Kazaa business to Atrinsic, obtaining all licenses to the content offered as part of the Kazaa business and delivering that content to subscribers. As part of the agreements, we are required to make advance payments and expenditures of certain expenses incurred in order to operate the Kazaa business. These advances and expenditures are recoverable on a dollar for dollar basis against revenues generated by the business.

Beginning in April 2010, we began to take steps to eliminate unprofitable or marginally profitable lead generation activities and marketing programs from our product offerings, to focus the Company on businesses our Board believes will be more likely to generate long term value for our stockholders.

On October 13, 2010, we entered into amendments to the Agreements with Brilliant Digital and entered into an agreement with Brilliant Digital and Altnet, Inc., a wholly-owned subsidiary of Brilliant Digital, to acquire all of the assets of Brilliant Digital that relate to its Kazaa digital music service.

Among other things, the amendments extend the term of the Agreements from three years to thirty years, provide us with an exclusive license to the Kazaa trademark in connection with our services under the agreements, and modify the Kazaa digital music service profit share payable to us under the agreements from 50% to 80%.directors deems relevant. In addition, the amendments remove Brilliant Digital’s obligation to repay up to $2.5 million of advances and expenditures which are not otherwise recovered from Kazaa generated revenues and remove a $5 million cap on expenditures that we are required to advance to the operation of the Kazaa business. As consideration for entering into the amendments, we issued 1,040,358 shares of our common stock to Brilliant Digital.

5


On October 13, 2010, in addition to the amendments to the Agreements, we entered into an asset purchase agreement with Brilliant Digital to acquire all of the assets of Brilliant Digital that relate to the Kazaa business.  The purchase price for the acquired assets includes the issuance of an additional 1,781,416 shares of our common stock at the closing of the transaction, as well as the assumption of certain liabilities related to the Kazaa business. The closing of the transaction contemplated by the asset purchase agreement will occur when all of the assets associated with the Kazaa business, including the Kazaa trademark and associated intellectual property, as well as Brilliant Digital’s content management, delivery and customer service platforms, and licenses with third parties, have been transferred to us. The closing of the transaction is subject to approval by both our stockholders and Brilliant Digital’s stockholders, receipt of all necessary third party consents as well as other customary closing conditions. At the closing of the transactions contemplated by the asset purchase agreement, we have agreed to appoint two individuals to be selected by Brilliant Digital to serve on our Board. In addition, at the closing, the Marketing Services Agreement and Master Services Agreement will terminate.

In connection with our announcement on October 14, 2010 to purchase the Kazaa assets, we also announced the implementation of a restructuring of our existing operations and of the operations of the Kazaa digital music subscription business.  The restructuring is designed to rapidly reduce certain expenditures, improve product development and sales and to improve customer acquisition outcomes for the company in general as well as for the Kazaa digital music service.  The restructuring involves the consolidation of activities in New York, the reduction in our Canadian workforce, and migration of our Canadian technology assets to pre-existing infrastructure in the U.S.  In addition, certain functions and activities involving the development of the Kazaa service and application development, as well as marketing are consolidating.

On May 31, 2011, we and certain investors (the selling stockholders hereunder), entered into a Securities Purchase Agreement (the “Purchase Agreement”) and consummated the transactions contemplated thereby simultaneously with the execution thereof (the “Financing”).  Pursuant to the terms of the Purchase Agreement, we sold to the selling stockholders convertible notes in the aggregate original principal amount of $5,813,500 (the “Notes”), which Notes are convertible into shares of our common stock. The Notes were issued with an original issue discount of approximately 9.1%, and the aggregate purchase price of the Notes was $5,285,000. The Notes are not interest bearing, unless we are in default on the Notes, in which case the Notes carry an interest rate of 18% per annum until the applicable default is cured.  As further discussed below, we also agreed to issue to each selling stockholder warrants to acquire shares of common stock, in the form of three warrants: (i) “Series A Warrants,” (ii) “Series B Warrants” and (iii) “Series C Warrants” (collectively, the “Warrants”).

Corporate Information
We are a Delaware corporation. The address of our principal executive office is 469 7th Avenue, 10th Floor, New York, NY 10018, and our telephone number is (212) 716-1977.  Our website address is www.atrinsic.com.  The information that can be accessed through viewing our website is not part of this prospectus.

6


About the Offering
Description of Notes

The Notes issued in connection with the Financing are initially convertible into shares of common stock at a conversion price of $2.90 per share, provided that if we make certain dilutive issuances (with limited exceptions), the conversion price of the Notes will be lowered to the per share price paid in the applicable dilutive issuance.   We are required to repay the Notes in six equal monthly installments commencing on December 31, 2011 and ending on May 31, 2012, either in cashany future debt or in shares of our common stock. If we choose to utilize shares of our common stock for all or part of the payment, we must make an irrevocable decision to use shares 23 trading days prior to the installment payment date, and the value of our shares will be equal to the lower of the conversion price then in effect or 85% of the arithmetic average of the closing bid prices of our common stock during the 20 trading day period prior to payment of the installment amount (the “Installment Conversion Price”). If we choose to make an installment payment in shares of common stock, we must make a pre-installment payment of shares (the “Pre-Installment Shares”) to the Note holder 21 trading days prior to the applicable installment date based on the value of our shares equal to the lower of the conversion price then in effect or 85% of the arithmetic average of the closing bid prices of our common stock during the 20 trading day period prior to delivery of the Pre-Installment Shares. On the installment date, to the extent we owe a Note holder additional shares in excess of the Pre-Installment Shares to satisfy the installment payment, we will issue such Note holder additional shares, and to the extent we have issued excess Pre-Installment Shares, such shares will be applied to future payments.  The Company does not currently have enough cash to make all of the payments due on the Notes and does not anticipate sufficient cash flowcredit financings may preclude us from operations to enable it to repay the Notes in full with cash.  Therefore, the Company currently intends to repay the Notes through the issuance of shares of its common stock.  However, this intention may change depending on the Company’s finances at the time of the applicable payment date and the Company’s stock price on the applicable payment date.
If an event of default occurs under the Notes, each Note holder may require us to redeem its Note in cash at the greater of up to 110% of the unconverted principal amount or 110% of the greatest equity value of the shares of common stock underlying such Note holder’s Note from the date of the default until the redemption is completed.
The conversion price of each Note is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions. The convertibility of each Note may be limited if, upon conversion, the holder or any of its affiliates would beneficially own more than 4.9% or 19.9% (as applicable) of our common stock.

Description of Warrants

The Warrants issued in connection with the Financing are convertible into shares of common stock. The Series B Warrants are exercisable immediately after issuance and expire nine months after the date we obtain shareholder approval (discussed below). The Series B Warrants provide that the holders are initially entitled to purchase an aggregate of 1,002,329 shares at an initial exercise price of $2.93 per share.  If we make certain dilutive issuances (with limited exceptions), the exercise price of the Series B Warrants will be lowered to the per share price paid in the applicable dilutive issuance. The number of shares underlying the Series B Warrants will adjust whenever the exercise price adjusts, such that at all times the aggregate exercise price of the Series B Warrants will be $2,936,824.
To the extent we enter into a fundamental transaction (as defined in the Series B Warrants and which include, without limitation, our entering into a merger or consolidation with another entity, our selling all or substantially all of our assets, or a person acquiring 50% of our common stock), we have agreed to purchase the Series B Warrants from the holders at their Black-Scholes value (if a holder so elects to have its Series B Warrant so purchased).
If our common stock trades at a price at least 200% above the Series B Warrants exercise price for a period of 10 trading days at any time after we obtain shareholder approval (discussed below), we may force the exercise of the Series B Warrants if we meet certain conditions.
The Series A and Series C Warrants are exercisable immediately after issuance and have a five year term. The Series A Warrants provide that the holders are initially entitled to purchase an aggregate of 2,004,658 shares at an initial exercise price of $2.90 per share. The Series C Warrants provide that the holders are initially entitled to purchase an aggregate of 952,212 shares at an initial exercise price of $2.97 per share. If on the expiration date of the Series B Warrants, a holder of such warrant has not exercised such warrant for at least 80% of the shares underlying such warrant, we have the right to redeem from such holder its Series C Warrant for $1,000 under certain circumstances.

7

If we make certain dilutive issuances (with limited exceptions), the exercise price of the Series A and Series C Warrants will be lowered to the per share price paid in the applicable dilutive issuance. The number of shares underlying the Series A Warrants and the Series C Warrants will adjust whenever the exercise price adjusts, such that at all times the aggregate exercise price of the Series A Warrants and Series C Warrants will be $5,813,502 and $2,828,070, respectively.
To the extent we enter into a fundamental transaction (as defined in the Series A and Series C Warrants and which include, without limitation, our entering into a merger or consolidation with another entity, our selling all or substantially all of our assets, or a person acquiring 50% of our common stock), we have agreed to purchase the Series A and Series C Warrants from the holder at their Black-Scholes value (if a holder so elects to have its Series A Warrant or Series C Warrant so purchased).
The exercise price of all the Warrants is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions. The exercisability of the Warrants may be limited if, upon exercise, the holder or any of its affiliates would beneficially own more than 4.9% or 19.9% (as applicable) of our common stock. The Notes may not be converted and the Warrants may not be exercisable if the total number of shares that would be issued would exceed 19.99% of our common stock on the date the Purchase Agreement was executed prior to our receiving shareholder approval (as discussed below).

Description of Security Agreement

We and our subsidiaries, New Motion Mobile, Inc. and Traffix, Inc. entered into a security agreement (“Security Agreement”) with the selling stockholders pursuant to which we granted each of the selling stockholders a security interest in all of our assets securing our obligations under the Notes. In addition, New Motion Mobile, Inc. and Traffix, Inc. executed guaranties (each, a “Guaranty”) with each selling stockholder pursuant to which such subsidiaries guarantee our obligations under the Notes.

Description of Registration Rights

In connection with the Financing, we also entered into a registration rights agreement (“Registration Rights Agreement”) with the selling stockholders pursuant to which, among other things, we agreed to register the resale of 133% of the shares of common stock underlying the Notes and Warrants. We agreed to file a registration statement by June 30, 2011 and to the extent we fail to file the registration statement on a timely basis or if the registration statement is not declared effective within 90 days after the closing of the transaction (120 days if reviewed by the Securities and Exchange Commission), we agreed to make certain payments to the selling stockholders.  The registration statement of which this prospectus is a part is being filed to satisfy the foregoing obligations.
Shareholder Approval; Other Covenants in Purchase Agreement
In the Purchase Agreement, we have agreed to, among other things, (i) subject to certain exceptions, not issue any securities for a period beginning on May 31, 2011 to the date that is 30 trading days from the date on which the resale by the selling stockholders of all registrable securities (as defined in the Registration Rights Agreement) is covered by one or more registration statements, (ii) not to enter into a variable rate transaction at any time while the Notes are outstanding, (iii) for a period of one year from the date of the Purchase Agreement, to allow the selling stockholders to participate in future financing transactions; and (iv) to hold a shareholder meeting by August 15, 2011 to approve, among other matters, the issuance of greater than 19.99% of our shares of common stock pursuant to the Notes and upon exercise of the Warrants and to approve any change of control and/or other matter requiring approval which results from the issuance of our shares of common stock pursuant to the Notes and upon exercise of the Warrants.  The Company intends to hold its shareholder meeting as promptly as practicable.

8


Use of Prospectus

This prospectus may be used only in connection with the resale by the selling stockholders of up to 5,963,857 shares of our common stock.  paying dividends.

USE OF PROCEEDS

We will not receive any of the proceeds from the sale of any shares of our common stock offered by the selling stockholders pursuant tounder this prospectus. On September 29, 2011, we had 6,330,778 shares of our common stock outstanding, which excludes 681,509 shares held in treasury.


9


RISK FACTORS
Investing in our common stock involves a high degree of risk. You should carefully consider the following risk factors and all other information contained in this report before purchasing our common stock. The risks and uncertainties described below are not the only ones facing us. Additional risks and uncertainties that management is unaware of, or that it currently deems immaterial, also may become important factors that affect us. If any of the following risks occur, our business, financial condition, cash flows and/or results of operations could be materially and adversely affected. In that case, the trading price of our common stock could decline, and stockholders are at risk of losing some or all of the money invested in purchasing our common stock.

Risks Related to Our Business
There is substantial doubt about our ability to continue as a going concern.

Our consolidated financial statements are prepared using accounting principles generally accepted in the United States applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The accompanying historical consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.

The assessment of our ability to continue as a going concern was made by management considering, among other factors: (i) our current levels of expenditures, including subscriber acquisition costs, operating expense, including product development, and overhead, (ii) our ongoing working capital needs, (iii) the uncertainty concerning the outcome of any financing, (iv) our history of losses and use of cash for operating activities (v) outstanding balance of cash and cash equivalents of $2.3 million at the end of the quarter ended June 30, 2011, and (vi) our budgets and financial projections of future operations, including the likelihood of achieving operating profitability without the need for additional financing.

For periods subsequent to June 30, 2011, we expect losses if we continue to incur expenditures to develop the Kazaa digital music service, acquire subscribers for the Kazaa service, and if we are not able to reduce other operating expenses and overhead sufficiently to a level in line with our level of revenues.  If we are unable to increase revenues sufficiently or decrease our expenditures to a sustainable level, our financial position, results of operations, cash flows and liquidity will continue to be materially adversely affected. These conditions raise substantial doubt about our ability to continue as a going concern.

Based on current financial projections, we believe the continuation of our Company as a going concern is primarily dependent on our ability to, among other factors: (i) consummate a suitable financing, or obtain cash from the sale of our assets or lines of business, (ii) scale our Kazaa subscriber base to a level where the monthly revenue generated from our subscriber base exceeds subscriber acquisition costs, net of expenses required to operate Kazaa, (iii) eliminate or reduce operating and overhead expenditures to a level more in line with our revenue, (iv) improve utilization of the Kazaa digital music service and improve LTVs of subscribers to that service,  (v) acquire profitable subscribers to the Kazaa digital music service at cost effective rates, (vi) grow our search marketing agency revenue base through the addition of new customers or expansion of business with existing customers and, (vii) expand margins in our search marketing agency and on our affiliate platform.  While we address these operating matters, we must continue to meet expected near-term obligations, including normal course operating cash requirements and costs associated with developing and operating the Kazaa digital music service, as well as funding overhead and the working capital needs of our other businesses.  If we are not able to obtain sufficient funds through a financing, or if we experience adverse outcomes with respect to our operational forecasts, our financial position, results of operations, cash flows and liquidity will continue to be materially adversely affected.

10


In the near term, we are focused on: (i) raising additional debt or equity capital to fund our immediate cash needs and to finance our longer term growth to further develop the Kazaa business and grow our subscriber base, and (ii) pursuing various means to minimize operating costs and increase cash including through the sale of assets or business. We cannot provide assurance that we will be able to realize the cost reductions in our operations, or that we can obtain additional cash through asset sales or the issuance of equity on favorable terms, or at all. If we are unsuccessful in our efforts we will be required to further reduce our operations, including further reductions of our employee base, or we may be required to cease certain or all of our operations in order to offset the lack of available funding.

We continue to evaluate the sale of certain of our assets and businesses. We cannot provide any assurance that we will be successful in finding suitable purchasers for the sale of such assets.  Even if we are able to find purchasers, we may not be able to obtain attractive terms and conditions for such sales, including attractive pricing. In addition, divestitures of businesses involve a number of risks, including the diversion of management and employee attention, significant costs and expenses, the loss of customer relationships, a decrease in revenues associated with the divested business, and the disruption of operations in the affected business. Furthermore, divestitures potentially involve significant post-closing separation activities, which could involve the expenditure of significant financial and employee resources. An inability to consummate identified asset sales or manage the post-separation transition arrangements could adversely affect our business, financial condition, results of operations and cash flows.

The Convertible Note financing may result in significant dilution for existing stockholders.

On May 31, 2011, we entered into a securities purchase agreement with certain buyers pursuant to which we sold the Notes and Warrants.  Both the Notes and Warrants contain “down round” provisions, which provides that if the Company makes certain dilutive issuances, the conversion price of the Notes and the strike price of the Warrants will be lowered to the per share price paid in the applicable dilutive issuance.  The Company is required to repay the Notes in six equal monthly installments commencing on December 31, 2011 and ending on May 31, 2012, either in cash or in shares of its common stock. The Company does not currently have sufficient cash available to repay the Notes.  If the Company chooses to utilize shares of its common stock to repay the Notes, the value of the Company’s shares will be equal to the lower of the conversion price then in effect or 85% of the average closing bid prices of its common stock during the 20 trading day period prior to payment of the installment amount.  Both the down round terms of the Notes and Warrants, and the payment of the installments in stock rather than cash could result in significant dilution to current stockholders.

If we default on our convertible notes, we may lose all of our assets and intellectual property.
Our obligations under the Notes issued on May 31, 2011 are secured pursuant to the terms of a Security Agreement entered into by Atrinsic and certain of our subsidiaries and the buyers of such Notes. Pursuant to the Security Agreement, we granted each of the buyers a security interest in all of our assets. In addition, certain of our subsidiaries executed guaranties with the buyers pursuant to which such subsidiaries guarantee our obligation under the Notes. In the event we default under the Notes, the Note holders may obtain our assets, including all of our intellectual property. If we lose all or a substantial portion of our assets, our shares will significantly decline in value or become worthless.

11

��

We currently are operating our business with vacancies in several key executive positions.

In order to effectively operate our business and effect the necessary growth to meet our financial needs, the company is required to continuously set key strategic objectives and develop strategies to meet these objectives. This function requires competent leadership within our organization. Due to recent turnover of key executives, we are currently operating with several vacancies in invaluable executive positions. If we are unable to attract and retain qualified officers to fill these roles, our business, operating results and growth can be adversely affected.

If our purchase of the Kazaa assets does not close, the price of our common stock could decline and our future business and operations could be harmed.

The Company's and Brilliant Digital’s obligations to complete the purchase and sale of the Kazaa assets is subject to conditions, many of which are beyond the control of the parties. If the transaction is not completed for any reason:

·The price of our common stock may decline;
·We will incur costs related to the transaction, such as financial advisory, legal, accounting, proxy solicitation and printing fees, even if the transaction is not completed;
·We will not be able to realize the expected benefits of the acquisition which are a significant component of our growth strategy; and
·We may not be able to operate as effectively under the existing Marketing Services Agreement and Master Services Agreement, which agreements are to remain in place if the transaction does not close,

all of which may harm our business and operations.

We have experienced a significant reduction in revenue and have been using cash to fund operations. If we cannot halt this revenue decline and reduce expenditures we may have to cease operations.

The Company has experienced a significant revenue decline and degradation in business prospects over the past two years, and as a result the Company has used a significant amount of cash to fund its operations.  The Company’s cash and cash equivalents were $2.3 million as of June 30, 2011, which is a $4.0 million decline from the $6.3 million as of December 31, 2010.  If we are unsuccessful at stabilizing or slowing the decline in our revenue, and our associated use of cash to fund operations, or if we cannot raise cash through financing alternatives, then we will need to significantly curtail or cease operations.

The working capital requirements for companies in the digital music industry is significant.

The digital music industry is highly competitive and as a result of the industry’s characteristics, subjects market participants to significant working capital requirements, as is evidenced by the numerous companies in the industry that have experienced significant losses.  If we are to attract and retain talented employees, acquire subscribers and enhance and improve the Kazaa digital music service, which we will need to do if we are to be successful, we will have significant capital requirements.  There is no guarantee additional capital will be available on favorable terms or at all.

12

We will require additional capital to pursue our business objectives and respond to business opportunities, challenges or unforeseen circumstances. If capital is not available to us or is available to us but on unfavorable terms, our business, operating results and financial condition may be harmed.
We will require additional capital to operate or expand our business. In addition, some of our current or future strategic initiatives, including continued growth of the Kazaa line of business, will require substantial additional capital resources before they begin to generate revenue. Additional funds may not be available when we need them, on terms that are acceptable to us, or at all. In addition, volatility in the credit markets may have an adverse effect on our ability to obtain debt or equity financing. If we do not have funds available to enhance our business, maintain the competitiveness of our technology and pursue business opportunities, we may not be able to service our existing subscribers and customers, or acquire new subscribers or customers, which could have an adverse effect on our business, operating results and financial condition.

We face risks in implementing our restructuring plan.

In connection with our announcement to purchase the assets of the Kazaa digital music service, we are undertaking a restructuring of our existing operations.  Although the reorganization and consolidation of activities are expected to yield cost savings as a result of the reduction in headcount, the elimination of duplicative activities and combining or eliminating networking and other overhead costs, there can be no assurance that we will achieve the forecasted savings.  Our remaining business may also suffer as a result of the restructuring due to the loss of employees, who have been involuntarily terminated, or employees who leave voluntarily.  We may also face defections from customers who are unsure of our viability and may also receive less favorable terms than we currently receive from our vendors, as a result of their perception of the restructuring.  There can be no assurance that the restructuring will be completed effectively, with limited negative impact on our business.

As part of our restructuring plan and in connection with the integration of activities with the Kazaa business, we will be migrating many of our technological assets.  We face risks with such migrations, including disruptions in service.  Also, the costs and time associated with any migration could be substantial, requiring the reengineering of computer systems and telecommunications infrastructure.  We may also face interruptions in the services we provide across all of our business activities. In addition to service interruptions arising from third-party service providers, unanticipated problems affecting our proprietary internal computer and telecommunications systems have the potential to occur in future fiscal periods, and could cause interruptions in the delivery of services, causing a loss of revenue and related gross margins, and the potential loss of customers, all of which could materially and adversely affect our business, results of operations and financial condition.

The anticipated benefits of the acquisition of the Kazaa business may not be realized fully or at all or may take longer to realize than expected.

The integration of Atrinsic and the business of Kazaa face challenges as a result of the differing geographical locations of the two businesses. In the event the transactions contemplated by the asset purchase agreement close, the combined company will be required to devote significant management attention and resources to integrating the Kazaa business and the assets into our operations.  Delays in this process could adversely affect our business, financial results, financial condition and stock price. Even if we are able to integrate the business operations successfully, there can be no assurance that this integration will result in the realization of the full benefits of synergies, cost savings, innovation and operational efficiencies that may be possible from this integration or that these benefits will be achieved within a reasonable period of time.

13


We face intense competition in the sale of our subscription services and transactional services.

In our subscription service business, which includes the Kazaa music service, and our transactional services business, we compete primarily on the basis of marketing acquisition cost, brand awareness, consumer penetration and carrier and distribution depth and breadth.  We face numerous competitors, many of whom are much larger than us, who have greater financial and operating resources than we do and who have been operating in our target markets longer than we have.  In the future, likely competitors may include other major media companies, traditional video game publishers, telephone carriers, content aggregators, wireless software providers and other pure-play direct response marketers publishing content and media, and internet affiliate and network companies.

If we are not as successful as our competitors in executing on our strategy in targeting new markets and increasing customer penetration in existing markets our sales could decline, our margins could be negatively impacted and we could lose market share, any and all of which could materially harm our business prospects, and potentially have a negative impact on our share price.

We may continue to be impacted by the effects of the current weakness of the United States economy.

Our performance is subject to United States economic conditions and its impact on levels of consumer spending.   Consumer spending recently has deteriorated significantly as a result of the current economic situation in the United States and may remain depressed, or be subject to further deterioration for the foreseeable future.  Purchases of our subscription based services as well as our transactional and marketing services have declined in periods of recession or uncertainty regarding future economic prospects, as disposable income declines. Many factors affect the level of spending for our products and services, including, among others: prevailing economic conditions, levels of employment, salaries and wage rates, interest rates, the availability of consumer credit, taxation and consumer confidence in future economic conditions. During periods of recession or economic uncertainty, we may not be able to maintain or increase our sales to existing customers or make sales to new customers on a profitable basis. As a result, our operating results may be adversely and materially affected by downward trends in the United States or global economy, including the current downturn in the United States which has impacted our business, and which may continue to affect our results of operations.

Our business relies on wireless and landline carriers and aggregators to facilitate billing and collections in connection with our subscription products sold and services rendered. The loss of, or a material change in, any of these relationships could materially and adversely affect our business, operating results and financial condition.

We generate a significant portion of our revenues from the sale of our products and services directly to consumers which are billed through aggregators and telephone carriers. We expect that we will continue to bill a significant portion of our revenues through a limited number of aggregators for the foreseeable future, although these aggregators may vary from period to period. In a risk diversification and cost saving effort, we have established a direct billing relationship with a carrier that mitigates a portion of our revenue generation risk as it relates to aggregator dependence; conversely this risk is replaced with internal performance risk regarding our ability to successfully process billable messages directly with the carrier. Moreover, in an effort to further mitigate such operational risk, we obtained a 36% equity stake in a landline telephone aggregator, TBR, to give us more visibility in the billing and collection process associated with subscription services billed to customers of local exchange carriers.

14


Our aggregator agreements are not exclusive and generally have a limited term of less than three years with automatic renewal provisions upon expiration in the majority of the agreements. These agreements set out the terms of our relationships with the aggregator and carriers, and provide that either party to the contract can terminate such agreement prior to its expiration, and in some instances, terminate without cause.

Many other factors exist that are outside of our control and could impair our carrier relationships, including:
·a carrier’s decision to suspend delivery of our products and services to its customer base;
·a carrier’s decision to offer its own competing subscription applications, products and services;
·a carrier’s decision to offer similar subscription applications, products and services to its subscribers for price points less than our offered price points, or for free;
·a network encountering technical problems that disrupt the delivery of, or billing for, our applications;
·the potential for concentrations of credit risk embedded in the amounts receivable from the aggregator should any one, or group of aggregators encounter financial difficulties, directly or indirectly, as a result of the current period of slower economic growth affecting the United States; or
·a carrier’s decision to increase the fees it charges to market and distribute our applications, thereby increasing its own revenue and decreasing our share of revenue.

If one or more carriers decide to suspend the offering of our subscription services, we may be unable to replace such revenue source with an acceptable alternative, within an acceptable time frame. This could cause us to lose the capability to derive revenue from those subscribers, which could materially harm our business, operating results and financial condition.

We depend on third-party Internet and telecommunications providers, over whom we have no control, for the conduct of our subscription business and transactional and marketing business. Interruptions in or the discontinuance of the services provided by one of the providers could have an adverse effect on revenue; and securing alternate sources of these services could significantly increase expenses and cause significant interruption to both our transactional and marketing and subscription businesses.

We depend heavily on several third-party providers of Internet and related telecommunication services, including hosting and co-location facilities, in conducting our business. These companies may not continue to provide services to us without disruptions in service, at the current cost or at all. The costs and time associated with any transition to a new service provider would be substantial, requiring the reengineering of computer systems and telecommunications infrastructure to accommodate a new service provider to allow for a rapid replacement and return to normal network operations. In addition, failure of the Internet and related telecommunications providers to provide the data communications capacity in the time frame required by us could cause interruptions in the services we provide across all of our business activities. In addition to service interruptions arising from third-party service providers, unanticipated problems affecting our proprietary internal computer and telecommunications systems have the potential to occur in future fiscal periods, and could cause interruptions in the delivery of services, causing a loss of revenue and related gross margins, and the potential loss of customers, all of which could materially and adversely affect our business, results of operations and financial condition.

15


We depend on partners and third-parties for our content and for the delivery of services underlying our subscriptions.

We depend heavily on partners and third parties to provide us with licensed content including for the Kazaa music service. We are reliant on such companies to maintain licenses with content providers, including music labels, so that we can deliver services that we are contractually obligated to deliver to our customers. These companies may not continue to provide services to us without disruption, or maintain licenses with the owners of the delivered content. In addition to licensed content, we are also reliant on partners and third parties to provide services and to perform other activities which allow us to bill our subscribers. The costs associated with any transition to a new service or content provider would be substantial, even if a similar partner is available. Failure of our partners or other third parties to provide content or deliver services has the potential to cause interruptions in the delivery of services, causing a loss of revenue and related gross margins, and the potential loss of customers, all of which could materially and adversely affect our business, results of operations and financial condition.

We may not fully recoup the expenses and other costs we have expended with respect to the Kazaa music service.

On March 26, 2010, we entered into three-year Marketing Services Agreement and Master Services Agreement with Brilliant Digital, effective July 1, 2009, relating to the operation and marketing of the Kazaa digital music service.  Under the agreements, we are responsible for marketing, promotional, and advertising services.  In exchange for these marketing services, the Company is entitled to full recoupment for all pre-approved costs and expenses incurred in connection with the provision of the services plus all other agreed budgeted amounts. On October 13, 2010, Atrinsic entered into amendments to its existing Marketing Services Agreement and Master Services Agreement with Brilliant Digital.  The amendments extend the term of each of the Marketing Services Agreement and Master Services Agreement from three years to thirty years, provide Atrinsic with an exclusive license to the Kazaa trademark in connection with Atrinsic’s services under the agreements, and modify the Kazaa digital music service profit share payable to Atrinsic under the agreements from 50% to 80%. In addition, the amendments remove Brilliant Digital’s obligation to repay up to $2.5 million of advances and expenditures which are not otherwise recovered from Kazaa generated revenues and remove the cap on expenditures that Atrinsic is required to advance in relation to the operation of the Kazaa business.

As of June 30, 2011, the Company has received the $2.5 million in repayments from Brilliant Digital and we are dependent on the future net cash flow of the Kazaa music service to fully recoup the approximately $13.9 million of advances and expenditures we have made, net of cash received or reimbursed, as of June 30, 2011. There can be no assurance that the future net cash flows from the Kazaa music service will be sufficient to allow us to fully recoup our expenditures, which could materially and adversely affect our financial condition.

If advertising on the internet loses its appeal, our revenue could decline.

All of our revenue is generated, directly or indirectly, through the Internet in part by delivering advertisements that generate leads, impressions, click-throughs, and other actions to our advertiser customers' websites as well as confirmation and management of mobile services. This business model may not continue to be effective in the future for various reasons, including the following:

·click and conversion rates may decline as the number of advertisements and ad formats on the Web increases, making it less likely that a user will click on our advertisement;
·the installation of "filter" software programs by web users which prevent advertisements from appearing on their computer screens or in their email boxes may reduce click-throughs;

16


·companies may be reluctant or slow to adopt online advertising that replaces, limits or competes with their existing direct marketing efforts;
·companies may prefer other forms of Internet advertising we do not offer, including certain forms of search engine placements;
·companies may reject or discontinue the use of certain forms of online promotions that may conflict with their brand objectives;
·companies may not utilize online advertising due to concerns of "click-fraud", particularly related to search engine placements;
·regulatory actions may negatively impact certain business practices that we currently rely on to generate a portion of our revenue and profitability; and
·perceived lead quality.

If the number of companies who purchase online advertising from us does not grow, we will experience difficulty in attracting publishers, and our revenue will decline.

If we are unable to successfully keep pace with the rapid technological changes that may occur in the wireless communication, internet and e-commerce arenas, we could lose customers or advertising inventory and our revenue and results of operations could decline.

To remain competitive, we must continually monitor, enhance and improve the responsiveness, functionality and features of our services, offered both in our subscription and transactional and marketing activities. Wireless network and mobile phone technologies, the Internet and the online commerce industry in general are characterized by rapid innovation and technological change, changes in user and customer requirements and preferences, frequent new product and service introductions requiring new technologies to facilitate commercial delivery, as well as the emergence of new industry standards and practices that could render existing technologies, systems, business methods and/or our products and services obsolete or unmarketable in future fiscal periods. Our success in our business activities will depend, in part, on our ability to license or internally develop leading technologies that address the increasingly sophisticated and varied needs of prospective consumers, and respond to technological advances and emerging industry standards and practices on a timely-cost-effective basis. Website and other proprietary technology development entails significant technical and business risks, including the significant cost and time to complete development, the successful implementation of the application once developed, and time period for which the application will be useful prior to obsolescence. There can be no assurance that we will use internally developed or acquired new technologies effectively or adapt existing websites and operational systems to customer requirements or emerging industry standards. If we are unable, for technical, legal, financial or other reasons, to adopt and implement new technologies on a timely basis in response to changing market conditions or customer requirements, our business, prospects, financial condition and results of operations could be materially adversely affected.

17


We could be subject to legal claims, government enforcement actions, and be held accountable for our or our customers' failure to comply with federal, state and foreign laws, regulations or policies, all of which could materially harm our business.

As a direct-to-consumer marketing company, we are subject to a variety of federal, state and local laws and regulations designed to protect consumers that govern certain of aspects of our business. For instance, recent growing public concern regarding privacy and the collection, distribution and use of information about Internet users has led to increased federal, state and foreign scrutiny and legislative and regulatory activity concerning data collection and use practices. Any failure by us to comply with applicable federal, state and foreign laws and the requirements of regulatory authorities may result in, among other things, indemnification liability to our customers and the advertising agencies we work with, administrative enforcement actions and fines, class action lawsuits, cease and desist orders, and civil and criminal liability.

We are subject to continued listing requirements on the NASDAQ Capital Market and if we are unable to meet such listing requirements, we could face delisting.

We are subject to continued listing requirements on the NASDAQ Capital Market, which includes such criteria as a $2.5 million minimum stockholders’ equity value requirement, as set forth in Listing Rule 5450(a)(1).  As of June 30, 2011, the value of our stockholders’ equity is a negative $1.1 million.

The value of our stockholders’ equity can be increased through equity financing or through additions to retained earnings (or reductions in accumulated deficit).  We are actively seeking to engage in an additional equity financing, but there can be no assurance that we will be successful in this regard. If we are not successful in raising equity capital, or even if we are successful, if we continue to incur net losses (which will negatively impact the value of our stockholders’ equity), we are not likely to be able to meet or maintain the minimum stockholders’ equity value requirement to maintain our listing on the NASDAQ Capital Market.

On May 31, 2011, we entered into a securities purchase agreement with certain buyers pursuant to which we sold the Notes and Warrants.  The securities purchase agreement contains a covenant that we maintain the listing of our Common Stock on the Nasdaq Capital Market.  The failure to maintain such listing is an event of default under the Notes.  Our obligations under the Notes are secured pursuant to the terms of a Security Agreement entered into by Atrinsic and certain of our subsidiaries and the buyers of such Notes.  Pursuant to the Security Agreement, we granted each of the buyers a security interest in all of our assets. In addition, certain of our subsidiaries executed guaranties with the buyers pursuant to which such subsidiaries guarantee our obligation under the Notes. In the event we fail to maintain our listing on the Nasdaq Capital Market, the Note holders may obtain our assets, including all of our intellectual property.  If we lose all or a substantial portion of our assets, our shares will significantly decline in value or become worthless.

We do not intend to pay dividends on our equity securities.

It is our current and long-term intention that we will use all cash flows to fund operations and maintain excess cash requirements for the possibility of potential future acquisitions. Future dividend declarations, if any, will result from our reversal of our current intentions, and would depend on our performance, the level of our then current and retained earnings and other pertinent factors relating to our financial position. Prior dividend declarations should not be considered as an indication for the potential for any future dividend declarations.

18


System failures could significantly disrupt our operations, which could cause us to lose customers or content.

Our success depends on the continuing and uninterrupted performance of our systems. Sustained or repeated system failures that interrupt our ability to provide services to customers, including failures affecting our ability to deliver advertisements quickly and accurately and to process visitors' responses to advertisements, and, validate mobile subscriptions, would reduce significantly the attractiveness of our solutions to advertisers and Web publishers. Our business, results of operations and financial condition could also be materially and adversely affected by any systems damage or failure that impacts data integrity or interrupts or delays our operations. Our computer systems are vulnerable to damage from a variety of sources, including telecommunications failures, power outages, malicious or accidental human acts, and natural disasters. Through the end of 2010, we operated a data center in Canada.  We have begun the process of closing down and transferring data to servers owned by third parties in 2011  and have a co-location agreement with a service provider to support our operations. Therefore, any of the above factors affecting any of these areas could substantially harm our business. Moreover, despite network security measures, our servers are potentially vulnerable to physical or electronic break-ins, computer viruses and similar disruptive problems in part because we cannot control the maintenance and operation of our third-party data centers. Despite the precautions taken, unanticipated problems affecting our systems could cause interruptions in the delivery of our solutions in the future and our ability to provide a record of past transactions. Our data centers and systems incorporate varying degrees of redundancy. All data centers and systems may not automatically switch over to their redundant counterpart. Our insurance policies may not adequately compensate us for any losses that may occur due to any failures in our systems.

We have been named as a defendant in litigation, either directly, or indirectly, with the outcome of such litigation being unpredictable; a materially adverse decision in any such matter could have a material adverse effect on our financial position and results of operations.

As described under the heading “Commitments and Contingencies,” or "Legal Proceedings" in our periodic reports filed pursuant to the Securities Exchange Act of 1934, from time to time we are named as a defendant in litigation matters. The defense of these claims may divert financial and management resources that would otherwise be used to benefit our operations. Although we believe that we have meritorious defenses to the claims made in each and all of the litigation matters to which we have been a named party, whether directly or indirectly, and intend to contest each lawsuit vigorously, no assurances can be given that the results of these matters will be favorable to us. A materially adverse resolution of any of these lawsuits could have a material adverse effect on our financial position and results of operations.

We may incur liabilities to tax authorities in excess of amounts that have been accrued which may adversely impact our results of operations and financial condition.

We have recorded significant income tax receivables. In November 2009 Congress passed the Worker Homeownership & Business Assistance Act of 2009 which allows businesses to carryback operating losses for up to 5 years. As a result of this Act we were able to carryback some of our 2009 taxable loss, resulting in a refund of $2.7 million, which was received in 2010. In the event that we are not able to successfully defend our tax positions, we may incur significant additional income tax liabilities and related interest and penalties which may have an adverse impact on our results of operations and financial condition.

If our efforts to attract prospective subscribers and to retain existing subscribers pertaining to our Kazaa business are not successful, our growth prospects and revenue will be adversely affected.

Our ability to grow our business and generate subscriber revenue depends on retaining and expanding our subscriber base. We must convince prospective listeners of the benefits of our service and existing listeners of the continuing value of our service.

Our ability to increase the number of our subscribers depends on effectively addressing a number of challenges and we may fail to do so. Some of these challenges include:

19


Providing subscribers with a consistent high quality, user-friendly and personalized experience;
continuing to build our catalog of music content that our listeners enjoy; and
continuing to innovate and keep pace with changes in technology and our competitors.

We depend upon third-party licenses for musical works and a change to or loss of these licenses could increase our operating costs or adversely affect our ability to retain and expand our listener base, and therefore could adversely affect our business.

To secure the rights to stream musical works embodied in sound recordings over the internet, Brilliant Digital maintains licenses from or for the benefit of copyright owners and pays royalties to copyright owners or their agents. We reimburse Brilliant Digital for these royalty payments.  These royalty payments represent a substantial cost in operating the Kazaa business.  Those who own copyrights in musical works are vigilant in protecting their rights and seek royalties that are very high in relation to the revenue that can be generated from the public performance of such works. There is no guarantee that the licenses available to Brilliant Digital now will continue to be available in the future or that such licenses will be available at the royalty rates associated with the current licenses. If we or Brilliant Digital are unable to secure and maintain rights to stream musical works or if we cannot do so on terms that are acceptable to us, our ability to stream music content to our listeners, and consequently our ability to attract subscribers, will be adversely impacted.

In order to stream musical works embodied in sound recordings over the internet, we must obtain public performance licenses and pay license fees to three performing rights organizations: Broadcast Music, Inc., or BMI, SESAC, Inc., or SESAC, and the American Society of Composers, Authors and Publishers, or ASCAP. These organizations represent the rights of songwriters and music publishers, negotiate with copyright users such as Brilliant Digital, collect royalties and distribute those royalties to the copyright owners they represent, namely songwriters and music publishers. Performing rights organizations have the right to audit our playlists and royalty payments, and any such audit could result in disputes over whether we have paid the proper royalties. If such a dispute were to occur, we could be required to pay additional royalties and the amounts involved could be material.

If our security systems are breached, we may face civil liability and public perception of our security measures could be diminished, either of which would negatively affect our ability to attract listeners and advertisers.

Techniques used to gain unauthorized access are constantly evolving, and we may be unable to anticipate or prevent unauthorized access to data pertaining to our listeners, including credit card information and other personally identifiable information. If an actual or perceived breach of security occurs of our systems or a vendor’s systems, we may face civil liability and public perception of our security measures could be diminished, either of which would negatively affect our ability to attract subscribers. We also would be required to expend significant resources to mitigate the breach of security and to address related matters.

We cannot control the actions of third parties who may have access to the subscriber data we collect. If such third parties’ use of subscriber data is not in compliance with the terms of our privacy policies, or if they fail to prevent unauthorized access to, or use of or disclosure of, subscriber information, we could be hindered or prevented in our efforts with respect to future growth opportunities.
Any failure, or perceived failure, by us to maintain the security of data relating to our listeners and employees, to comply with our posted privacy policy, laws and regulations, rules of self-regulatory organizations, industry standards, and contractual provisions to which we may be bound, could result in the loss of confidence in us, or result in actions against us by governmental entities or others, all of which could result in litigation and financial losses, and could potentially cause us to lose listeners, advertisers, revenue, and employees.
20


We are subject to a number of risks related to credit card and debit card payments we accept.

We accept payments through credit card transactions. For credit card payments, we pay processing and other fees, which may increase over time. An increase in those fees would require us to either increase the prices we charge for our products, or suffer an increase in our operating expenses, either of which could adversely affect our business, financial condition and results of operations.

If we or any of our processing vendors have problems with our billing software, or the billing software malfunctions, it could have an adverse effect on our subscriber satisfaction and could cause one or more of the major credit card companies to disallow our continued use of their payment products. In addition, if our billing software fails to work properly and, as a result, we do not automatically charge our subscribers’ credit cards on a timely basis or at all, our business, financial condition and results of operations could be adversely affected.

We are also subject to payment card association operating rules, certification requirements and rules governing electronic funds transfers, which could change or be reinterpreted to make it more difficult for us to comply. We must remain fully compliant with the Payment Card Industry, or PCI, Data Security Standard, or PCI DSS, a security standard with which companies that collect, store, or transmit certain data regarding credit, credit card holders, and credit card transactions are required to comply. Our failure to comply fully with PCI DSS may violate payment card association operating rules, federal and state laws and regulations, and the terms of our contracts with payment processors and merchant banks. Such failure to comply fully also may subject us to fines, penalties, damages, and civil liability, and may result in the loss of our ability to accept credit card payments. Further, there is no guarantee that, even if PCI DSS compliance is achieved, we will maintain PCI DSS compliance or that such compliance will prevent illegal or improper use of our payment systems or the theft, loss, or misuse of data pertaining to credit and debit cards, credit and debit card holders and credit and debit card transactions.

If we fail to adequately control fraudulent credit card transactions, we may face civil liability, diminished public perception of our security measures and significantly higher credit card-related costs, each of which could adversely affect our business, financial condition and results of operations.

If we are unable to maintain our chargeback rate or refund rates at acceptable levels, credit card companies may increase our transaction fees or terminate their relationships with us. Any increases in our credit card could adversely affect our results of operations, particularly if we elect not to raise our rates for our service to offset the increase. The termination of our ability to process payments on any major credit card would significantly impair our ability to operate our business.

21


FORWARD-LOOKING STATEMENTS
This prospectus contains “forward-looking statements” that include information relating to future events, future financial performance, strategies, expectations, competitive environment, regulation and availability of resources of Atrinsic. These forward-looking statements include, without limitation, statements regarding: proposed new services including, without limitation, the Company’s Kazaa digital music subscription service; the Company’s expectations concerning litigation, regulatory developments or other matters; statements concerning projections, predictions, expectations, estimates or forecasts for the Company’s business, financial and operating results and future economic performance; statements of management’s goals and objectives; and other similar expressions concerning matters that are not historical facts. Words such as “may,” “will,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes” and “estimates,” and similar expressions, as well as statements in future tense, identify forward-looking statements.
Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of when, or how, that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause these differences include, but are not limited to:
·our limited cash and ability to operate as a going concern;
·the risk that our Kazaa asset purchase does not close;
·the highly competitive and resource intensive market in which we operate;
·our ability to develop and market our products and services;
·costs and requirements as a public company; and
·other factors, including those discussed under the heading “Risk Factors”.
Forward-looking statements speak only as of the date they are made. You should not put undue reliance on any forward-looking statements. We assume no obligation to update forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. If we do update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.
USE OF PROCEEDS
We will not receive any proceeds from the sale of shares toof common stock under this prospectus will be offeredreceived by the selling stockholders. TheWe are required to pay certain offering fees and expenses in connection with the registration of the selling stockholders’ securities and to indemnify the selling stockholders against certain liabilities. Please see “Selling Stockholders” for a list of the persons receiving proceeds from the sale of the common stock covered by this prospectus.

SELLING STOCKHOLDERS

The following table sets forth information as of July 31, 2021 about the beneficial ownership of our common stock by the selling stockholders both before and immediately after the offering.

Except as otherwise noted in the table below, each of the Selling Stockholders acquired the shares being offering in connection with offerings exempt from registration under the Securities Act in 2016 or earlier. Of those shares that were not issued in exempt sales in 2016 and earlier, 79,500 shares of common stock were issued to the underwriters as restricted stock following our April 26, 2021 offering of common stock (“April 26 Offering”) as part of the underwriting compensation.

We believe, based on the information furnished to us, that the selling stockholders have sole voting and investment power with respect to all of the shares of common stock reported, subject to community property laws where applicable, unless otherwise indicated.

The percent of beneficial ownership for the selling stockholders is based on 16,339,649 shares of common stock issued and outstanding as of July 31, 2021. Unless otherwise stated in the footnotes to the table below and the information incorporated herein by reference, to our knowledge.

Pursuant to Rules 13d-3 and 13d-5 of the Exchange Act, beneficial ownership includes any shares of our common stock as to which a stockholder has sole or shared voting power or investment power, and also any shares of our common stock which the stockholder has the right to acquire within 60 days, including upon exercise of stock options or other rights to purchase shares of our common stock.

Because each selling stockholder’s common stocksecurity holder may dispose of all, none or some portion of their securities, no estimate can be given as to the number of securities that will belongbe beneficially owned by a selling security holder upon termination of this offering. Please read “Plan of Distribution.” For purposes of the table below, however, we have assumed that after termination of this offering none of the securities covered by this prospectus will be beneficially owned by the selling security holders and further assumed that the selling security holders will not acquire beneficial ownership of any additional securities during the offering. In addition, the selling security holders may have sold, transferred or otherwise disposed of, or may sell, transfer or otherwise dispose of, at any time and from time to that selling stockholder.


22


SELLING STOCKHOLDERS
time, our securities in transactions exempt from the registration requirements of the Securities Act after the date on which the information in the table is presented.

The shares of common stock being offered pursuant to this prospectus may be offered for sale from time to time during the period the registration statement of which this prospectus is a part remains effective, by or for the account of the selling stockholders. After the date of effectiveness, the selling stockholders may have sold or transferred, in transactions covered by this prospectus or in transactions exempt from the registration requirements of the Securities Act, some or all of their common stock. We may amend or supplement this prospectus from time to time in the future to update or change this selling security holders list and the securities that may be resold.

Except as described below, the selling stockholders are those issuableneither broker-dealers nor affiliates, as defined in Rule 405, of broker-dealers.

8

Name of selling stockholder Shares beneficially owned prior to this offering(1)  Shares to be offered by this  Shares beneficially owned after this offering 
  Number  Percentage  prospectus  Number  Percentage 
Garo H. Armen(2)(3)**  2,546,012   15.6%  2,546,012      %
Remik Hartounian**  442,194   2.7%  442,194      %
University of Toronto(4)**  271,200   1.7%  271,200      %
Mark Berg**  255,000   1.6%  255,000      %
Greg Ekizian**  225,000   1.4%  225,000      %
Larry N. Feinberg**  200,000   1.2%  200,000      %
Denis J. Hickey**  

200,000

   

1.2

%  

200,000

   

   

%

William Kachioff**  187,986   1.2%  187,986      %
Nicole Berg**  167,194   1.0%  167,194      %
Louis Sanzo**  150,000   0.9%  150,000      %
Richard Pashayan**  150,000   0.9%  150,000      %
David Lovejoy(3) **  148,800   0.9%  148,800      %
Richard & Christine Payne**  120,000   0.7%  120,000      %
Alexander K. Arrow(3) **  118,260   0.7%  118,260      %
Ethos Holding, LLC (5)**  100,000   0.6%  100,000      %
Khajak Keledjian**  100,000   0.6%  100,000      %
Timothy McInerney**  100,000   0.6%  100,000      %
SRAX, Inc. (6)**  99,061   *%  99,061      %
Dasa Sada, LLC(7)**  80,000   *%  80,000      %
Neil Vaccaro**  80,000   *%  80,000      %
Joseph Perri**  80,000   *%  80,000      %
Peter & Rita Ungaro, JTWROS (8)**  80,000   *%  80,000      %
Carmine Sanzo**  75,000   *%  75,000      %
Kevin McColl**  72,000   *%  72,000      %
Daniel Vaccaro**  60,000   *%  60,000      %
Robert Caswell**  56,000   *%  56,000      %
Khalil Barrage(2) **  50,000   *%  50,000      %
MSB Family Trust (9)**  50,000   *%  50,000      %
Sharon Crowder**  50,000   *%  50,000      %
Anthony Venditti**  50,000   *%  50,000      %
Brandt Mandia**  40,000   *%  40,000      %
Glenn S. Abel **  40,000   *%  40,000      %
Prieur, C. James & Karen Ann Prieur, JTWROS (10)**  40,000   *%  40,000      %
Robin Rosenthal**  40,000   *%  40,000      %
Lillian Tom**  40,000   *%  40,000      %
Michael Collado**  40,000   *%  40,000      %
Gregory Pappas**  40,000   *%  40,000      %
Robert Petrozzo  40,000   *%  40,000      %
Denis P. Hickey**  

40,000

   *%  

40,000

      %
Alan Young**  35,000   *%  35,000      %
Susan Rotzinger  35,000   *%  35,000      %
Thomas Halling**  32,400   *%  32,400      %
David W. Boral (11)***  32,198   *%  32,198      %
Joseph T. Rallo (11)***  32,197   *%  32,197      %
Carol Haggerty**  25,000   *%  25,000      %
Patricia Sorbara**  31,000   *%  31,000      %
John Moraitis**  25,000   *%  25,000      %
Dean Glasser**  25,000   *%  25,000      %
Levon Capan **  25,000   *%  25,000      %
Kerry Anne Wentworth **  25,000   *%  25,000      %
Mark Mazzer **  25,000   *%  25,000      %
Robert G. Jeffers**  25,000   *%  25,000      %
Stephen Dinicolantonio**  25,000   *%  25,000      %
Thomas D. Paul**  25,000   *%  25,000      %
Gordon Wong**  20,000   *%  20,000      %
Martin & Claudia Toner, JTWROS(12)**  20,000   *%  20,000      %
Robert Granito **  20,000   *%  20,000      %
Dalia Barsyte(3) **  10,000   *%  10,000      %
Jennifer Mandia**  10,000   *%  10,000      %
Massimo Martinucci**  10,000   *%  10,000      %
Benchmark Investments, LLC(13)***  7,155   *%  7,155      %
Patrick Sturgeon (14)***  3,200   *%  3,200      %
Michael Fontaine (14)***  1,250   *%  1,250      %
Graham Powis (14)***  1,250   *%  1,250      %
Robert Donohue (14)***  1,000   *%  1,000      %
Reilly Simmons (14)***  500   *%  500      %
Max Breckenridge (14)***  750   *%  750      %

* Represents less than 0.5%.

** Subject to contractual lock-up until October 23, 2021

*** Subject to contractual lock-up until April 24, 2022

9

(1)Beneficial ownership is determined in accordance with Rule 13d-3 under the Exchange Act.
(2)Member of the Company’s board of directors.
(3)Member of the Company’s management team.
(4)The selling shareholder, University of Toronto, is the registered owner of shares of common stock. The jurisdiction of the selling shareholder is Canada. Jennifer Frazer has voting and investment power over the shares of common stock. Ms. Frazer disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein.
(5)The selling shareholder, Ethos Holding, LLC., is the registered owner of shares of common stock. The jurisdiction of the selling shareholder is the United States. Cynthia Hackel has voting and investment power over the shares of common stock. Ms. Hackel disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. The selling shareholder received the common stock offered in this offering in the February 2016 offering.
(6)The selling shareholder SRAX, Inc., is the registered owner of shares of common stock. The jurisdiction of the selling shareholder is the United States.   Christopher Miglino has voting and investment power over the shares of common stock. Mr. Miglino disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. The selling shareholder received the common stock offered in this offering in 2020 as payment in kind for services rendered.
(7)The selling shareholder, Dasa Sada LLC, is the registered owner of shares of common stock. The jurisdiction of the selling shareholder is the United States. Donald Motschwiller has voting and investment power over the shares of common stock. Mr. Motschwiller disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. The selling shareholder received the common stock offered in this offering in the February 2016 offering.
(8)As tenants of the Peter & Rita Ungaro, JTWROS, Peter and  Rita Ungaro may be deemed to have voting and investment discretion over the securities identified herein.
(9)The selling shareholder, MSB Family Trust, is the registered owner of shares of common stock. The jurisdiction of the selling shareholder is the United States. Michael Blechman has voting and investment power over the shares of common stock.  Mr. Blechman disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.  The selling shareholder received the common stock offered in this offering in the February 2016 offering.
(10)As tenants of the C. James  Prieur & Karen Ann Prieur, JTWROS, C. James  Prieur & Karen Ann Prieur may be deemed to have voting and investment discretion over the securities identified herein.
(11)The selling stockholder is an employee of EF Hutton, Division of Benchmark Investments, Inc., which is a registered broker-dealer that acted as sole bookrunning manager in the April 26 Offering.
(12)As tenants of the Martin & Claudia Toner, JTWROS, Martin and Claudia Toner may be deemed to have voting and investment discretion over the securities identified herein.
(13)The selling stockholder is an affiliate of EF Hutton, Division of Benchmark Investments, Inc., which is a registered broker-dealer that acted as sole bookrunning manager in the April 26 Offering.
(14)The selling stockholder is an employee of Brookline Capital Markets, a division of Arcadia Securities, LLC, which is a registered broker-dealer that acted as an underwriter in the April 26 Offering.

10

DESCRIPTION OF CAPITAL STOCK

The following is a description of our Common Stock, $0.0001 par value (the “Common Stock”) and Preferred Stock, $0.000001 par value (the “Preferred Stock”). The Common Stock is the selling stockholders upon conversiononly security of the Notes and exercise of the Warrants. For additional information regarding the issuance of the Notes and the Warrants, see “Prospectus Summary – About the Offering” above. We are registering the shares of common stock in order to permit the selling stockholders to offer the shares for resale from time to time.

Brilliant Digital, one of the selling stockholders, which prior to the issuance of the Notes and Warrants held approximately 16.5% of our issued and outstanding common stock, purchased Notes in the aggregate principal amount of $2,200,000.  Prior to the financing, the Company and Brilliant Digital entered into a Marketing Services Agreement and a Master Services Agreement, each effective as of July 1, 2009,registered pursuant to which the companies jointly offer the Kazaa digital music service.  Each of the Marketing Services Agreement and the Master Services Agreement were amended on October 13, 2010.  The amendments to the agreements are part of a broader transaction between the Company and Brilliant Digital pursuant to which the Company will acquire all of the assets of Brilliant Digital that relate to its Kazaa digital music service business in accordance with the terms of an asset purchase agreement entered into between the parties on October 13, 2010.  Except for the ownership of the Notes and the Warrants issued pursuant to the Securities Purchase Agreement and as disclosed above with respect to Brilliant Digital, the selling stockholders have not had any material relationship with us within the past three years.
The table below lists the selling stockholders and other information regarding the beneficial ownership (as determined under Section 13(d)12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

We are authorized to issue is 120,000,000 shares of all classes of capital stock, of which 100,000,000 shares are Common Stock, $0.001 par value per share, and 20,000,000 shares are Preferred Stock, $0.000001 par value per share. Our capital is stated in U.S. dollars. As of July 31, 2021, we had 16,339,649 outstanding shares of Common Stock.

Common Stock

Voting. The holders of our common stock are entitled to one vote for each share held of record on all matters on which the rulesholders are entitled to vote (or consent pursuant to written consent).

Dividends. The holders of our common stock are entitled to receive, ratably, dividends only if, when and regulations thereunder)as declared by our board of directors out of funds legally available therefor and after provision is made for each class of capital stock having preference over the common stock. We have never declared or paid dividends. We do not intend to pay cash dividends on our common stock for the foreseeable future, but currently intend to retain any future earnings to fund the development and growth of our business. The payment of dividends if any, on our common stock will rest solely within the discretion of our board of directors and will depend, among other things, upon our earnings, capital requirements, financial condition, and other relevant factors.

Liquidation Rights. In the event of our liquidation, dissolution or winding-up, the holders of our common stock are entitled to share, ratably, in all assets remaining available for distribution after payment of all liabilities and after provision is made for each class of capital stock having preference over the common stock.

Conversion Rights. The holders of our common stock have no conversion rights.

Preemptive and Similar Rights. The holders of our common stock have no preemptive or similar rights.

Redemption/Put Rights. There are no redemption or sinking fund provisions applicable to the common stock. All of the outstanding shares of our common stock are fully-paid and non-assessable.

Preferred Stock

Under the terms of our Third Amended and Restated Certificate of Incorporation, our board of directors have the authority, without further action by our stockholders, to issue up to 20,000,000 shares of Preferred Stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares of common stock held by each of the selling stockholders. The second column listswholly unissued series and any qualifications, limitations or restrictions thereon, and to increase or decrease the number of shares of common stock beneficially owned byany such series, but not below the selling stockholders, based on their respective ownership of shares of common stock, notes and warrants, as of September 29, 2011, assuming conversion of the Notes and exercise of the Warrants held by each such selling stockholder on that date but taking account of any limitations on conversion and exercise set forth therein.

The third column lists the shares of common stock being offered by this prospectus by the selling stockholders and does not take into account any limitations on (i) conversion of the Notes set forth therein or (ii) exercise of the Warrants set forth therein.
In accordance with the terms of a registration rights agreement with the holders of the Notes and the Warrants, this prospectus generally covers the resale of the sum of (i) the maximum number of shares of common stock issuable uponsuch series then outstanding. The powers, preferences and relative, participating, optional and other special rights of each series of Preferred Stock, and the qualifications, limitations or restrictions thereof, if any, may differ from those of any and all other series at any time outstanding.

Our board of directors may authorize the issuance of Preferred Stock with voting or conversion rights that could adversely affect the voting power or other rights of the Notesholders of our Common Stock. The purpose of authorizing our board of directors to issue Preferred Stock and (ii)determine its rights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of Preferred Stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the maximum numbereffect of delaying, deferring or preventing a change in control of us and may adversely affect the market price of our Common Stock and the voting and other rights of the holders of our Common Stock. It is not possible to state the actual effect of the issuance of any shares of common stock issuable upon exercisePreferred Stock on the rights of holders of Common Stock until the board of directors determines the specific rights attached to that Preferred Stock.

11

Anti-Takeover Effect of Delaware Law, Certain Charter and Bylaw Provisions

In addition to the provisions included in our Third Amended and Restated Certificate of Incorporation and Bylaws, we are subject to the provisions of Section 203 of the Warrants, in each case, determined as if the outstanding Notes and Warrants were converted or exercised (as the case may be) in full (without regard to any limitations on conversion or exercise contained therein) asGeneral Corporation Law of the trading day immediately precedingState of Delaware, an anti-takeover law. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a “business combination” with an “interested stockholder” for a period of three years after the date this registration statement was initially filed with the SEC. Because the conversion price of the Notestransaction in which the person became an interested stockholder, unless the business combination is approved in the following prescribed manner:

prior to the time of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;
upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding (1) shares owned by persons who are directors and also officers and (2) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; and

on or subsequent to the time of the transaction, the business combination is approved by the board and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock which is not owned by the interested stockholder.

Generally, for purposes of Section 203, a “business combination” includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. An “interested stockholder” is a person who, together with affiliates and associates, owns or, within three years prior to the exercise pricedetermination of interested stockholder status, owned 15% or more of a corporation’s outstanding voting securities.

Transfer Agent and Registrar

American Stock Transfer & Trust Company, LLC is the Warrants may be adjusted, the numbertransfer agent and registrar for our common stock.

12

PLAN OF DISTRIBUTION

Sale of shares that will actually be issued may be more or less than the number of shares being offeredCommon Stock by this prospectus. Selling Stockholders

The fourth column assumes the sale of all of the shares offered by the selling stockholders pursuant to this prospectus.

Under the terms of the Notes and the Warrants, no selling stockholder (excluding Brilliant Digital Entertainment, Inc.) may convert its Notes or exercise its Warrants to the extent (but only to the extent) such selling stockholder or any of its affiliates would beneficially own a numbertheir pledgees, donees, assignees, transferees and successors-in-interest may, from time to time, sell, separately or together, some or all of shares of our common stock which would exceed 4.9%.  Brilliant Digital Entertainment, Inc. may not convert its Notes or exercise its Warrants to the extent (but only to the extent) such selling stockholdercovered by this prospectus on Nasdaq or any of its affiliates would beneficially own a number of shares of our commonother stock which would exceed 19.9%.  The number of shares in the second column reflects these limitations. The selling stockholders may sell all, someexchange, market or none of their shares in this offering.  See “Plan of Distribution.”

23


The information presented in this table is basedtrading facility on 6,330,778 shares of our common stock outstanding on September 29, 2011, which excludes 681,509 shares held in treasury.  Each of the selling stockholders has represented that it is not a broker-dealer, or an affiliate of a broker dealer.
Name of Selling Stockholder 
Number of Shares of
Common Stock Owned
Prior to Offering
  
Maximum Number of
Shares of Common Stock
to be Sold Pursuant to
this Prospectus
  
Number of Shares of
Common Stock Owned
After Offering (1)
  
Percentage of Shares
Beneficially Owned
After Offering (1)(2)
 
             
Iroquois Master Fund Ltd.  326,191(3)  1,410,561(3)  -   - 
                 
Brilliant Digital Entertainment, Inc.  1,314,350(4)  2,256,898(4)  1,040,357   8.0%
                 
Hudson Bay Master Fund Ltd.  326,191(5)  1,128,449(5)  -   - 
                 
Liballo Investment Limited  326,191(6)  564,227(6)  -   - 
                 
AYM Aggressive Value Fund  282,113(7)  282,113(7)  -   - 
                 
Kamran Hakim  282,113(8)  282,113(8)  -   - 
                 
Joseph Tuchman  19,748(9)  19,748(9)  -   - 
                 
Philip Dollman  19,748(10)  19,748(10)  -   - 

(1)Assumes all shares registered hereby are sold.

(2)
Applicable percentage of ownership is based on 6,330,778 shares of Common Stock outstanding as of September 29, 2011 (which excludes 681,509 shares held in treasury) together with all applicable options, warrants and other securities convertible into shares of our Common Stock for such stockholder. Beneficial ownership is determined in accordance with the rules of the SEC, and includes voting and investment power with respect to shares. Shares of our Common Stock subject to options, warrants or other convertible securities exercisable within 60 days after September 29, 2011 are deemed outstanding for computing the percentage ownership of the person holding such options, warrants or other convertible securities, but are not deemed outstanding for computing the percentage of any other person. Except otherwise noted, the named beneficial owner has the sole voting and investment power with respect to the shares of Common Stock shown.

(3)Iroquois Capital Management, L.L.C. (“Iroquois Capital”) is the investment manager of Iroquois Master Fund Ltd. (“IMF”). Consequently, Iroquois Capital has voting control and investment discretion over securities held by IMF. As managing members of Iroquois Capital, Joshua Silverman and Richard Abbe make voting and investment decisions on behalf of Iroquois Capital in its capacity as investment manager to IMF. As a result of the foregoing, Mr. Silverman and Mr. Abbe may be deemed to have beneficial ownership (as determined under Section 13(d) of the Securities Exchange Act of 1934, as amended) of the securities held by IMF.

Column 2 includes 326,191 shares of common stock issuable upon conversion of a secured convertible note held by IMF. Excludes (i) 147,947 shares of common stock issuable upon conversion of such note held by IMF and (ii) 936,423 shares of common stock issuable upon exercise of warrants held by IMF because such note contains, and each of such warrants contain, a “blocker provision” under which the holder thereof does not have the right to convert such noteshares are traded or exercise each such warrant to the extent (but only to the extent) that such conversion or exercise would result in beneficial ownership by the holder thereof, or any of its affiliates, of more than 4.9% of the common stock. Without such “blocker provisions,” Iroquois Capital, Mr. Silverman and Mr. Abbe would be deemed to have beneficial ownership (as determined under Section 13(d) of the Securities Exchange Act of 1934, as amended) of 1,410,561 shares of common stock.

24


The maximum number of shares of common stock to be sold pursuant to this prospectus includes (i) 474,138 shares of the Company’s Common Stock reserved for issuance upon the conversion of convertible promissory notes and (ii) 936,423 shares of the Company’s Common Stock reserved for issuance upon the exercise of warrants.

(4)Kevin Bermeister, in his capacity as Chief Executive Officer of Brilliant Digital Entertainment, Inc., has voting control and investment discretion over securities held by Brilliant Digital Entertainment, Inc.  As a result of the foregoing, Mr. Bermeisterprivate transactions. These sales may be deemed to have beneficial ownership (as determined under Section 13(d) of the Securities Exchange Act of 1934, as amended) of the securities held by Brilliant Digital Entertainment, Inc.

Column 2 includes 1,040,357 shares of common stock and 273,993 shares of common stock issuable upon conversion of a secured convertible note held by Brilliant Digital Entertainment, Inc. Excludes (i) 484,628 shares of common stock issuable upon conversion of such note held by Brilliant Digital Entertainment, Inc. and (ii) 1,498,277 shares of common stock issuable upon exercise of warrants held by Brilliant Digital Entertainment, Inc. because such note contains, and each of such warrants contain, a “blocker provision” under which the holder thereof does not have the right to convert such note or exercise each such warrant to the extent (but only to the extent) that such conversion or exercise would result in beneficial ownership by the holder thereof, or any of its affiliates, of more than 19.9% of the common stock. Without such “blocker provisions,” Brilliant Digital Entertainment, Inc. and Kevin Bermeister would be deemed to have beneficial ownership (as determined under Section 13(d) of the Securities Exchange Act of 1934, as amended) of 3,297,255 shares of common stock.

The maximum number of shares of common stock to be sold pursuant to this prospectus includes (i) 758,621 shares of the Company’s Common Stock reserved for issuance upon the conversion of convertible promissory notes and (ii) 1,498,277 shares of the Company’s Common Stock reserved for issuance upon the exercise of warrants.

(5)Hudson Bay Capital Management LP is the Investment Manager of Hudson Bay Master Fund Ltd. Consequently, Hudson Bay Capital Management LP has voting control and investment discretion over securities held by Hudson Bay Master Fund Ltd.  As Investment Manager, Hudson Bay Capital Management LP makes voting and investment decisions on behalf of Hudson Bay Master Fund Ltd.  As a result of the foregoing, Hudson Bay Capital Management LP may be deemed to have beneficial ownership (as determined under Section 13(d) of the Securities Exchange Act of 1934, as amended) of the securities held by Hudson Bay Master Fund Ltd.  Sander Gerber is the managing member of Hudson Bay Capital GP LLC, which is the general partner of Hudson Bay Capital Management LP. Sander Gerber disclaims beneficial ownership over the securities held by Hudson Bay Master Fund Ltd.

Column 2 includes 326,191 shares of common stock issuable upon conversion of a secured convertible note held by Hudson Bay Master Fund Ltd.  Excludes (i) 53,120 shares of common stock issuable upon conversion of such note held by Hudson Bay Master Fund Ltd. and (ii) 749,138 shares of common stock issuable upon exercise of warrants held by Hudson Bay Master Fund Ltd. because such note contains, and each of such warrants contain, a “blocker provision” under which the holder thereof does not have the right to convert such note or exercise each such warrant to the extent (but only to the extent) that such conversion or exercise would result in beneficial ownership by the holder thereof, or any of its affiliates, of more than 4.9% of the common stock. Without such “blocker provisions,” Hudson Bay Master Fund Ltd. would be deemed to have beneficial ownership (as determined under Section 13(d) of the Securities Exchange Act of 1934, as amended) of 1,128,449 shares of common stock.

The maximum number of shares of common stock to be sold pursuant to this prospectus includes (i) 379,311 shares of the Company’s Common Stock reserved for issuance upon the conversion of convertible promissory notes and (ii) 749,138 shares of the Company’s Common Stock reserved for issuance upon the exercise of warrants.
25


(6)Dr. Johannes Burger is the director of Liballo Investment Ltd.  As director, Dr Burger makes voting and investment decisions on behalf of Liballo.  As a result of the foregoing, Mr. Burger may be deemed to have beneficial ownership (as determined under Section 13(d) of the Securities Exchange Act of 1934, as amended) of the securities held by Liballo Investment Ltd.

Column 2 includes 189,656 shares of common stock issuable upon conversion of a secured convertible note held by Liballo and 136,535 shares of common stock issuable upon exercise of warrants held by Liballo. Excludes 238,036 shares of common stock issuable upon exercise of warrants held by Liballo because each of such warrants contain, a “blocker provision” under which the holder thereof does not have the right to exercise each such warrant to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, or any of its affiliates, of more than 4.9% of the common stock. Without such “blocker provisions,” Liballo and Dr. Burger would be deemed to have beneficial ownership (as determined under Section 13(d) of the Securities Exchange Act of 1934, as amended) of 564,227 shares of common stock.

The maximum number of shares of common stock to be sold pursuant to this prospectus includes (i) 189,656 shares of the Company’s Common Stock reserved for issuance upon the conversion of convertible promissory notes and (ii) 374,571 shares of the Company’s Common Stock reserved for issuance upon the exercise of warrants.

(7)Abraham Muller is the Investment Manager of AYM Aggressive Value Fund, LP.  Consequently, Mr. Muller has voting control and investment discretion over securities held by AYM Aggressive Value Fund, LP. As Investment Manager, Mr. Muller makes voting and investment decisions on behalf of AYM Aggressive Value Fund, LP. As a result of the foregoing, Mr. Muller may be deemed to have beneficial ownership (as determined under Section 13(d) of the Securities Exchange Act of 1934, as amended) of the securities held by AYM Aggressive Value Fund, LP.

Column 2 includes 94,828 shares of common stock issuable upon conversion of a secured convertible note held by AYM Aggressive Value Fund, LP and 187,285 shares of common stock issuable upon exercise of warrants held by AYM.

The maximum number of shares of common stock to be sold pursuant to this prospectus includes (i) 94,828 shares of the Company’s Common Stock reserved for issuance upon the conversion of convertible promissory notes and (ii) 187,285 shares of the Company’s Common Stock reserved for issuance upon the exercise of warrants.

(8)Column 2 includes 94,828 shares of common stock issuable upon conversion of a secured convertible note held by Mr. Hakim and 187,285 shares of common stock issuable upon exercise of warrants held by Mr. Hakim.

The maximum number of shares of common stock to be sold pursuant to this prospectus includes (i) 94,828 shares of the Company’s Common Stock reserved for issuance upon the conversion of convertible promissory notes and (ii) 187,285 shares of the Company’s Common Stock reserved for issuance upon the exercise of warrants.

(9)Column 2 includes 6,638 shares of common stock issuable upon conversion of a secured convertible note held by Mr. Tuchman and 13,110 shares of common stock issuable upon exercise of warrants held by Mr. Tuchman.

The maximum number of shares of common stock to be sold pursuant to this prospectus includes (i) 6,638 shares of the Company’s Common Stock reserved for issuance upon the conversion of convertible promissory notes and (ii) 13,110 shares of the Company’s Common Stock reserved for issuance upon the exercise of warrants.

(10)Column 2 includes 6,638 shares of common stock issuable upon conversion of a secured convertible note held by Mr. Dollman and 13,110 shares of common stock issuable upon exercise of warrants held by Mr. Dollman.

The maximum number of shares of common stock to be sold pursuant to this prospectus includes (i) 6,638 shares of the Company’s Common Stock reserved for issuance upon the conversion of convertible promissory notes and (ii) 13,110 shares of the Company’s Common Stock reserved for issuance upon the exercise of warrants.

26


OTHER INFORMATION
The following is information pertaining to (i) payments the Company may make in connection with the Transaction and (ii) net proceeds and total possible payments in connection with the sale of Series A warrants, Series B warrants and Series C warrants (the “Warrants”) and the Notes (the “Transaction”).

(i)           Payments by the Company.  The Company has made payments in connection with the Transaction as set out in the table below.

Party Payments in Cash Other Payments
Iroquois Master Fund Ltd. $60,000 None

Pursuant to Section 4(g) of the Securities Purchase Agreement, the Company was required to reimburse Iroquois Master Fund Ltd., a selling stockholder, or its designees for all costs and expenses incurred by it or its affiliates in connection with the transactions contemplated by the Securities Purchase Agreement and documents relating thereto (including, without limitation, all legal fees and disbursements in connection therewith, structuring, documentation and implementation of the transactions contemplated by the Securities Purchase Agreement and documents relating thereto and due diligence and regulatory filings in connection therewith) in a non-accountable amount equal to $60,000.  The $60,000 paid at the time of the Transaction to Iroquois Master Fund Ltd. was for this purpose, and was not a fee paid to Iroquois Master Fund Ltd.

In addition, the Company will make or may be required to make payments to:

(a)           Selling shareholders: Other than as described above, the Company has not made any payments to the selling shareholders, and the Company is not required to make any payments to the Selling Shareholders apart from (i) the repayment of principal (the notes do not bear interest as they were issued at a 9.1% original discount), and (ii) in the event of default on the notes, an interest payment equal to 18% per annum during the term of the default.  It is not possible to calculate potential interest payments in the event of default under the Notes, as the amount of interest payable depends upon the duration of the event of default.  In addition, pursuant to the Registration Rights Agreement entered into in connection with the Transaction, the Company is required to make a cash payment equal to 1% of the investors’ original principal amount upon the occurrence of certain events relating to registration delays, and on every thirty day anniversary of such event until the delay is cured.

(b)           Persons related to selling shareholders: The Company has not made payments to any person related to a selling shareholder in regards to the Transaction and the registration of the underlying shares and is not required to make any such payments.  There are also no payments (including the value of any payments to be made in common stock) in connection with the transaction that the Company has made or may be required to make to any affiliate of a selling shareholder.

(c)           Persons with whom the selling shareholders had a contractual relationship: The Company has not made any payments to any person with whom the selling shareholders had a contractual relationship in regards to the Transaction and is not required to make any such payments.

27


(ii)           Net proceeds and total possible payments.  The gross proceeds from the Transaction were $5,285,000, of which $4,716,000 was received in cash.  The Company applied a $535,000 Demand Promissory Note against the gross proceeds, and $35,000 of expense reimbursement owed to Iroquois Master Fund Ltd.  In addition to these payments netted from the gross proceeds, the Company paid (i) an additional $25,000 in expense reimbursement to Iroquois Master Fund Ltd, (ii) $88,000 in legal fees to Stubbs Alderton & Markiles, LLP, counsel to the Company, (iii) a fee of $40,000 and expenses of approximately $85,000 to Asia Pacific Capital, a consultant to the Company, and (iv) a fee of approximately $167,250 and expenses of approximately $10,600 to Wedbush Securities, Inc., a consultant to the Company, resulting in net cash proceeds to the Company of $4,299,150.  All amounts due on the notes are due within, or on, one year of their issuance and, barring any penalties for late payments and/or other defaults, total $5,813,500.

Potential Profits to Note Holders Pursuant to Transaction

The following is information relating to the potential profit Note holders could receive in connection with the Transaction.  The total potential profit that the Note holders could realize depends on several factors, including whether (i) the Note holders are repaid in cash, (ii) the Note holders elect to convert the Notes and (iii) the Company elects to convert the Notes.

Under the terms of the Notes and the Warrants, no Note holder (excluding Brilliant Digital Entertainment, Inc.) may convert its Notes or exercise its Warrants to the extent (but only to the extent) such selling stockholder or any of its affiliates would beneficially own a number of shares of our common stock which would exceed 4.9%.  Brilliant Digital Entertainment, Inc. may not convert its Notes or exercise its Warrants to the extent (but only to the extent) such selling stockholder or any of its affiliates would beneficially own a number of shares of our common stock which would exceed 19.9%.  Until the selling shareholders are able to fully convert their Notes and exercise their Warrants, their ability to capture the profits described below will be limited.  The Company intends to hold a shareholder meeting as promptly as practicable to approve, among other matters, the issuance of greater than 19.99% of the Company’s shares of common stock pursuant to the Notes and upon exercise of the Warrants and to approve any change of control and/or other matter requiring approval which results from the issuance of our shares of common stock pursuant to the Notes and upon exercise of the Warrants.

 (i)          Repayment in Cash.

Assuming that all payments on the Notes are made in cash, the Note holders will make a profit of 10.0% on their investment, or $528,500, as that is the amount of the original issue discount contained in the face amount of the Notes and there is no interest on the Notes.

(ii)          Repayment by Conversion at Note Holders’ Election.

Subject to the limitations described above, at any time after the issuance of the Notes, the selling stockholders may convert their Notes into shares of the Company’s common stock by delivery of a notice of conversion to the Company.  The Notes are initially convertible into shares of common stock at a conversion price of $2.90 per share, provided that if the Company makes certain dilutive issuances (with limited exceptions), the conversion price of the Notes will be lowered to the per share price paid in the applicable dilutive issuance.  The following table sets out the potential profit to the Note holders at different market prices at the time of the Note holders’ conversion at a conversion price of $2.90 (assuming that the Note holders are able to sell all of those shares at that market price):

28


  Market Price/Conversion Price 
  $<2.90  $3.10  $3.30  $3.50  $3.70  $3.90 
% Profit  10%  17.59%  25.17%  32.76%  40.34%  47.93%
Total shares underlying converted notes  2,004,655   2,004,655   2,004,655   2,004,655   2,004,655   2,004,655 
Total Market Price of Shares Underlying Convertible Notes $5,813,500  $6,214,431  $6,615,362  $7,016,293  $7,417,224  $7,818,155 
Total Conversion Price of Shares Underlying Convertible Notes $5,813,500  $5,813,500  $5,813,500  $5,813,500  $5,813,500  $5,813,500 
Total Profit on Sale of Shares $0  $400,931  $801,862  $1,202,793  $1,603,724  $2,004,655 
Original Issue Discount on Notes Profit $528,500  $528,500  $528,500  $528,500  $528,500  $528,500 
Total Profit $528,500  $929,431  $1,330,362  $1,731,293  $2,132,224  $2,533,155 
(iii)         Repayment by Conversion at Company’s Election.

If the Company elects to convert the Notes, the conversion price will be the lesser of (a) $2.90 or (b) 85% of the arithmetic average of the closing bid prices of the Company’s common stock during the 20 trading day period prior to the applicable conversion.  The following table sets out the potential profit to the Note holders at different market prices at the time of the Company’s conversion (assuming (a) that the market price and the applicable average of the volume-weighted average prices are the same, (b) that the Company is eligible to convert and (c) the Note holders are able to sell all of those shares at that market price):

29


Market Price $2.50  $2.70  $2.90  $3.10  $3.30  $3.41 
Conversion Price $2.13  $2.30  $2.47  $2.64  $2.81  $2.90 
% Profit  29.4%  29.4%  29.4%  29.4%  29.4%  29.4%
Total shares underlying converted notes  2,735,765   2,533,116   2,358,418   2,206,262   2,072,550   2,005,693 
Total Market Price of Shares Underlying Convertible Notes $6,839,413  $6,839,413  $6,839,412  $6,839,412  $6,839,415  $6,839,413 
Total Conversion Price of Shares Underlying Convertible Notes $5,813,500  $5,813,500  $5,813,500  $5,813,500  $5,813,500  $5,813,500 
Total Profit on Sale of Shares or Total Discount to Market Price $1,025,912  $1,025,913  $1,025,912  $1,025,912  $1,025,915  $1,025,913 
Original Issue Discount on Notes Profit $528,500  $528,500  $528,500  $528,500  $528,500  $528,500 
Total Profit $1,554,412  $1,554,412  $1,554,412  $1,554,412  $1,554,412  $1,554,412 

The profit to the Note holders at any price above $3.41 are the same as in (ii) above.

There are provisions in the Notes that could change the conversion price, namely full-ratchet adjustments upon the issuance of securities at a per share price of less than $2.90.   The Company neither intends to enact nor anticipates such a share issuance that would trigger an adjustment to the conversion price.

Explanation of why profits on conversion may differ in a Company election versus a Note holder election

The profits on the conversion of the Notes at the Company’s election and at a Note holder’s election at the same market price may differ because the conversion prices can be different.  Conversion at the Note holder’s election is based on a fixed price ($2.90), and conversion at the Company’s election is based on the lower of the fixed price ($2.90) or a price equal to 85% of the arithmetic average of the closing bid prices of the Company’s common stock during the 20 trading day period prior to the applicable conversion.  For conversions at the Company’s election, the price will always be lower than the $2.90 fixed price when the market price/average of the volume-weighted average prices is below approximately $3.41.  Above that market price/average of the volume-weighted average prices, the conversion price (and percentage profit) at both the Company’s and Note holder’s election will be the same, $2.90. The examples below provides more detail and hypothetical examples.

30


(i)          Conversion at Holder’s Election. If a Note holder elects to convert, the conversion price is $2.90.  The Company provided the information in the above table for the conversion at the Note holder’s election assuming that the Note holder is able to sell all of those shares at the market price.

With a market price of $3.10, a hypothetical conversion of $1,000 at $2.90 would result in the Company issuing 345 shares to the Note holder. A Note holder selling all 345 shares at $3.10 would gross $1,069.50.  That is a profit of $69.50 on a $1,000 conversion, or a 6.95% profit (before taking into account the original issue discount profit).

(ii)          Conversion at Company’s Election. If the Company elects to convert the Notes, the conversion price will be the lesser of (a) $2.90 or (b) 85% of the arithmetic average of the closing bid prices of the Company’s common stock during the 20 trading day period prior to the applicable conversion.  The Company provided the information in the above table for the repayment at the Company’s election assuming that (a) the market price and the applicable average of the volume-weighted average prices are the same and (b) the Note holders are able to sell all of those shares at that market price.
As such, if the market price (and the applicable average of the volume-weighted average prices) is $3.10, the conversion price will be $2.635 (85% of $3.10). A hypothetical conversion of $1,000 at $2.635 would result in the Company issuing 380 shares. A Note Holder selling all 380 shares at $3.10 would gross $1,178.00.  That is a profit of $178.00 on a $1,000 conversion, or a 17.8% profit (before taking into account the original issue discount profit).

Explanation of why percentage profit remains the same regardless of the market price of the Company’s stock in a conversion at the Company’s election

As noted, the conversion price for conversion at the Company’s election is the lesser of (a) $2.90 or (b) 85% of the arithmetic average of the closing bid prices of the Company’s common stock during the 20 trading day period prior to the applicable conversion.  As 85% of $3.412 is $2.90, anytime the average of the volume-weighted average prices exceeds $3.412, the fixed price of $2.90 will be used for conversion at the Company’s election as that will be the lower conversion price. When the fixed conversion price of $2.90 is used for conversions at the Company’s election, it will result in the same percentage profit as when the fixed conversion price is used for conversions at the Note Holder’s election.

As for conversions at the Company’s election when the average of the volume-weighted average prices is below $3.412, the percentage profit is fixed at 17.647% (before taking into account the original issue discount on the Notes) as long as the Note holder can sell all shares received in the conversions at the market price.  For a conversion of $85 of Note principal at a stock price less than $3.412, the Note Holder will receive $100 of stock, which is a $15 profit on an $85 conversion (before taking into account the original issue discount on the Notes).

Additional Information Relating to Gross Proceeds, Payments, Resulting Proceeds to the Company and Investor Profit

Gross Proceeds to Company as a result of Transaction $5,285,000 
Required Payments (made or to be made in connection with the financing)(1)
 $450,850 
Resulting Net Proceeds to Issuer $4,834,150 
Total possible profit resulting from conversion discount upon Company conversion with a market price of approximately $3.41 or less (above $3.41, there is no conversion discount). $1,554,412 
31


(1)This excludes any payments that may be required to be made to selling stockholders as a result of an event of default under the Notes or as a result of registration delay payments that may be required to be made to the selling stockholders pursuant to the Registration Rights Agreement.

As a percentage, the total amount of all possible payments ($450,850) and the total possible discount to the market price of the shares underlying the convertible notes ($1,554,412)(assuming a Company conversion at a market price of $2.90 per share and including the original issue discount profit) divided by the gross proceeds to the issuer from the sale of the convertible notes ($5,285,000) is 37.9%, or 3.2% per month that the notes are outstanding based on the 12 month period of the notes.

PLAN OF DISTRIBUTION
We are registering the shares of common stock issuable upon conversion of the Notes and exercise of the Warrants to permit the resale of these shares of common stock by the holders of the Notes and Warrants from time to time after the date of this prospectus. We will not receive any of the proceeds from the sale by the selling stockholders of the shares of common stock. We will bear all fees and expenses incident to our obligation to register the shares of common stock.
The selling stockholders may sell all or a portion of the shares of common stock held by them and offered hereby from time to time directly or through one or more underwriters, broker-dealers or agents. If the shares of common stock are sold through underwriters or broker-dealers, the selling stockholders will be responsible for underwriting discounts or commissions or agent’s commissions. The shares of common stock may be sold in one or more transactions at fixed prices, at prevailing market prices at the time of sale, at prices related to the sale,prevailing market price, at varying prices determined at the time of sale, or at negotiated prices. These salesTo the extent any of the selling stockholders gift, pledge or otherwise transfer the securities offered hereby, such transferees may be effectedoffer and sell the securities from time to time under this prospectus, provided that, if required under the Securities Act, and the rules and regulations promulgated thereunder, this prospectus has been amended under Rule 424(b)(3) or other applicable provision of the Securities Act, they include the name of such transferee in transactions, whichthe list of selling stockholders under this prospectus. Subject to compliance with applicable law, the selling stockholders may involve crosses or block transactions, pursuant touse any one or more of the following methods:
methods when selling shares of common stock:

 ·on any national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale;
·in the over-the-counter market;
·in transactions otherwise than on these exchanges or systems or in the over-the-counter market;
·through the writing or settlement of options, whether such options are listed on an options exchange or otherwise;
·ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;the purchaser;
 ·
block trades in which the broker-dealer will attempt to sell the shares of common stock as agent but may position and resell a portion of the block as principal to facilitate the transaction;
 ·
purchases by a broker-dealer as principal and resale by the broker-dealer for its account;
 ·
an exchange distribution in accordance with the rules of the applicable exchange;
 ·
privately negotiated transactions;

32

 ·
“at the market” or through market makers or into an existing market for the shares of common stock;
through one or more underwritten offerings on a firm commitment or best efforts basis;
settlement of short sales madeentered into after the date the Registration Statement is declared effective by the SEC;of this prospectus;
 ·broker-dealers may agree
agreements with a selling securityholderbroker-dealers to sell a specified number of such shares of common stock at a stipulated price per share;
through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;

13

 ·through the distribution of common stock by any selling stockholder to its partners, members or securityholders;
a combination of any such methods of sale; andor
 ·
any other method permitted pursuant to applicable law.

To our knowledge, the selling stockholders have not entered into any agreements, understandings or arrangements with any underwriters or broker/dealers regarding the sale of the shares of common stock covered by this prospectus. At any time a particular offer of the shares of common stock covered by this prospectus is made, a revised prospectus or prospectus supplement, if required, will set forth the aggregate amount of shares of common stock covered by this prospectus being offered and the terms of the offering, including the name or names of any underwriters, dealers, brokers or agents. In addition, to the extent required, any discounts, commissions, concessions and other items constituting underwriters’ or agents’ compensation, as well as any discounts, commissions or concessions allowed or reallowed or paid to dealers, will be set forth in such revised prospectus or prospectus supplement. Any such required prospectus supplement, and, if necessary, a post-effective amendment to the registration statement of which this prospectus is a part, will be filed with the SEC to reflect the disclosure of additional information with respect to the distribution of the shares of common stock covered by this prospectus.

To the extent required, any applicable prospectus supplement will set forth whether or not underwriters may over-allot or effect transactions that stabilize, maintain or otherwise affect the market price of the common stock at levels above those that might otherwise prevail in the open market, including, for example, by entering stabilizing bids, effecting syndicate covering transactions or imposing penalty bids.

The selling stockholders may also sell shares of our common stock under Rule 144 promulgated under the Securities Act, of 1933, as amended, if available, or in other transactions exempt from registration, rather than under this prospectus. In addition,The selling stockholders have the sole and absolute discretion not to accept any purchase offer or make any sale of securities if they deem the purchase price to be unsatisfactory at any particular time.

Broker-dealers engaged by the selling stockholders may transfer the shares of common stock byarrange for other means not describedbrokers-dealers to participate in this prospectus.sales. If the selling stockholders effect such transactions by selling shares of common stocksecurities to or through underwriters, broker-dealers or agents, such underwriters, broker-dealers or agents may receive commissions in the form of discounts, concessions or commissions from the selling stockholders (and/or, commissions from purchasersif any broker-dealer acts as agent for the purchaser of the shares of common stock, for whom they may act as agent orfrom the purchaser) in amounts to whom they may sell as principal (which discounts, concessions or commissions as to particular underwriters, broker-dealers or agents may be in excess of those customary in the types of transactions involved). negotiated.

In connection with salesthe sale of the shares of common stock or otherwise,interests therein, the selling stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the shares of common stock in the course of hedging inthe positions they assume. The selling stockholders may also sell shares of the common stocksotck short after the effective date of the registration statement of which this prospectus is a part and deliver shares of common stock covered by this prospectusthese securities to close out their short positions, and to return borrowed shares in connection with such short sales. The selling stockholders may alsoor loan or pledge shares ofthe common stock to broker-dealers that in turn may sell such shares.

these securities. The selling stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).

The selling stockholders may from time to time pledge or grant a security interest in some or all of the Notes, Warrants ortheir shares of common stock owned by them and, if they default into their broker-dealers under the performancemargin provisions of theircustomer agreements or to other parties to secure other obligations. If a selling stockholder defaults on a margin loan or other secured obligations,obligation, the pledgeesbroker-dealer or secured partiesparty may, from time to time, offer and sell the shares of common stock from time to timepledged or secured thereby pursuant to this prospectus or any amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act amending, if necessary, the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling stockholders under this prospectus. The selling stockholders also may transfer and donate the shares of common stock in other circumstances in which case the transferees, donees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus.

To the extent required by the Securities Act and the rules and regulations thereunder, the selling stockholders and any broker-dealerother persons participating in the sale or distribution of the shares of common stock may be deemed to be “underwriters” within the meaning of the Securities Act, and any commission paid, or any discounts or concessions allowed to, any such broker-dealer may be deemed to be underwriting commissions or discounts under the Securities Act. At the time a particular offering of the shares of common stock is made, a prospectus supplement, if required, will be distributed, which will set forth the aggregate amount of shares of common stock being offered and the terms of the offering, including the name or names of any broker-dealers or agents, any discounts, commissions and other terms constituting compensation from the selling stockholders and any discounts, commissions or concessions allowed or re-allowed or paid to broker-dealers.
Under the securities laws of some states, the shares of common stock may be sold in such states only through registered or licensed brokers or dealers. In addition, in some states the shares of common stock may not be sold unless such shares have been registered or qualified for sale in such state or an exemption from registration or qualification is available and is complied with.

33

There can be no assurance that any selling stockholder will sell any or all of the shares of common stock registered pursuant to the registration statement, of which this prospectus forms a part.
The selling stockholders and any other person participating in such distribution will be subject to applicable provisions of the Securities Act and the Exchange Act, of 1934, as amended, and the rules and regulations thereunder, including, without limitation, to the extent applicable, Regulation MM. These provisions may restrict certain activities of, the Exchange Act, which mayand limit the timing of purchases and sales of any of the shares of common stock by, the selling stockholders andor any other participating person. To the extent applicable, Regulation M may also restrict the ability of any person, engaged in the distribution of the shares of common stock to engage in market-making activities with respect to the shares of common stock. All of the foregoingwhich limitations may affect the marketability of the shares of common stock and the ability of any person or entity to engage in market-making activities with respect tostock.

14

The selling stockholders also may transfer the shares of our common stock.

Westock in other circumstances, in which case the transferees, pledgees or other successors-in-interest will pay all expensesbe the selling beneficial owners for purposes of this prospectus.

A selling stockholder that is an entity may elect to make a pro rata in-kind distribution of shares of common stock to its members, partners or shareholders pursuant to the registration statement of which this prospectus is a part by delivering a prospectus. To the extent that such members, partners or shareholders are not affiliates of ours, such members, partners or shareholders would thereby receive freely tradeable shares of common stock pursuant to the distribution through a registration rights agreement, estimatedstatement.

The selling stockholders and any broker-dealers or agents that are involved in selling the shares of common stock may be deemed to be $63,367“underwriters” within the meaning of the Securities Act in total, including, without limitation,connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the shares of common stock purchased by them may be deemed to be underwriting commissions or discounts under the Securities and Exchange Commission filingAct. To our knowledge, no selling stockholder has entered into any agreement or understanding, directly or indirectly, with any person to distribute the shares of our common stock.

We are required to pay all fees and expenses incident to the registration of compliance with state securities or “blue sky” laws; provided, however, a selling stockholder will pay all underwriting discounts and selling commissions, if any.shares of our common stock. We willhave agreed to indemnify thecertain selling stockholders against certain losses, claims, damages and liabilities, including some liabilities under the Securities Act in accordance with the registration rights agreements orAct. We and the selling stockholders will be entitledmay agree to contribution. We may be indemnified by the selling stockholdersindemnify underwriters, broker-dealers or agents against civilcertain liabilities, including liabilities under the Securities Act, and may also agree to contribute to payments which the underwriters, broker-dealers or agents may be required to make.

There can be no assurance that may arise from any written information furnished to us by the selling stockholder specifically for use in this prospectus, in accordance withwill sell any or all of the related registration rights agreements or we may be entitledsecurities registered pursuant to contribution.


Once sold under the registration statement of which this prospectus formsis a part,part.

15

LEGAL MATTERS

The validity of the shares of common stocksecurities described in this prospectus will be freely tradable in the hands of persons other than our affiliates.


LEGAL MATTERS
Stubbs Alderton & Markiles, LLP, Sherman Oaks, California, will passpassed upon for us by Duane Morris LLP, New York, New York. If the securities are being distributed through underwriters or agents, the validity of the common stock offeredsecurities will be passed upon for the underwriters or agents by this prospectus.
counsel identified in the related prospectus supplement.

EXPERTS

The consolidated

Our financial statements of Atrinsic, Inc. as of December 31, 2010 and 2009 and for each of the years in the two-year period ended December 31, 2010, have been2020 and 2019 incorporated by reference in this Registration Statement, in reliance upon the reports of KPMGprospectus have been audited by MaloneBailey, LLP, independent registered public accounting firm, incorporated by reference elsewhere herein and are included in reliance on their report (the report on the financial statements contains an explanatory paragraph regarding the Company’s ability to continue as a going concern) given upon the authority of said firm as experts in accountingauditing and auditing. 


34


accounting.

LIMITATION ON LIABILITY AND DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, we will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by us is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

WHERE YOU CAN FIND MORE INFORMATION

This prospectus and any subsequent prospectus supplements do not contain all of the information in the Registration Statement. We have omitted from this prospectus some parts of the Registration Statement as permitted by the rules and regulations of the SEC. Statements in this prospectus concerning any document we have filed as an exhibit to the Registration Statement or that we otherwise filed with the SEC are not intended to be comprehensive and are qualified in their entirety by reference to these filings. In addition, we file annual, quarterly and current reports, proxy statements and other information with the SEC. We have filed with theThe SEC a Registration Statement on Form S-3/A under the Securities Act with respect to the shares of common stock we are offering under this prospectus. This prospectus does not contain all of the information set forth in the Registration Statement and the exhibits to the Registration Statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the Registration Statement and the exhibits and schedules filed as a part of the Registration Statement. You may read and copy the Registration Statement, as well as ourmaintains an Internet site that contains reports, proxy and information statements and other information that we file electronically with the SEC, including us. The SEC’s Internet site can be found at the SEC’s public reference room at 100 F Street, N.E., Room 1580, Washington, D.C. 20549-0102. You can requesthttp://www.sec.gov. In addition, we make available on or through our Internet site copies of these documents by writingreports as soon as reasonably practicable after we electronically file or furnished them to the SEC and paying a fee for the copying cost. You may obtain further information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330.SEC. Our SEC filings are also available on the SEC Internet site can be found at www.sec.gov, which contains periodic reports and other information regarding issuers that file electronically.


We also maintain a website at www.atrinsic.com, through which you can access our filings with the SEC. The information contained in, or accessible through, ourhttp:www.protagenic.com. Our website is not a part of this prospectus.

16

INFORMATION INCORPORATED BY REFERENCE


The SEC allows us

We have elected to “incorporateincorporate certain information by reference” informationreference into this prospectus, which means thatprospectus. By incorporating by reference, we can disclose important information to you by referring you to other documents that we have filed or will file with the SEC. We are incorporatingThe information incorporated by reference is deemed to be part of this prospectus, except for information incorporated by reference that is superseded by information contained in this prospectus. This means that you must look at all of the SEC filings that we incorporate by reference to determine if any statements in the prospectus or any document previously incorporated by reference have been modified or superseded. This prospectus incorporates by reference the information or documents set forth below that we have previously filed with the SEC (Commission File No. 000-50633):


our Annual Report on Form 10-K for the fiscal year ended December 31, 2010, which was filed on April 7, 2011 as amended on May 2, 2011;

our Quarterly Report on Form 10-Q for the quarter ended March 31, 2011, which was filed on May 16, 2011;

our Quarterly Report on Form 10-Q for the quarter ended June 30, 2011, which was filed on August 15, 2011;

our Current Report on Form 8-K filed July 1, 2011, which such report revised certain sections within our Annual Report on Form 10-K for the fiscal year ended December 31, 2010, to give retroactive effect to the change in reportable segments;

our Current Reports on Form 8-K filed February 25, 2011; April 1, 2011 (as to information therein explicitly filed with the SEC only); April 20, 2011; April 26, 2011; June 1, 2011; June 6, 2011; July 12, 2011, August 22, 2011 and September 15, 2011 (to the extent that items contained in the preceding Current Reports on Form 8-K are furnished but not deemed “filed” for purposes of Section 18 ofunder the Securities Exchange Act of 1934, as amended (or otherwise subject(the “Exchange Act”):

our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the Securities Exchange Commission on March 25, 2021;
our Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2021, filed with the Securities Exchange Commission on May 17, 2021;
our Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2021, filed with the Securities Exchange Commission on August 16, 2021;
our Current Reports on Form 8-K, filed with the Securities Exchange Commission on July 26, 2021 and August 19, 2021;
the description of our common stock set forth in the Registration Statement on Form 8-A12B filed with the Securities Exchange Commission on April 26, 2021, including any amendment or report filed for the purpose of updating such description.

We also incorporate by reference any future filings (other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed on such form that are related to such items unless such Form 8-K expressly provides to the liabilities of Section 18), such items are not incorporated by reference);


the description of our common stock contained in our registration statement on Form 10-SB filed with the SEC on June 10, 2005, including any amendments or reports filed for the purpose of updating such description, including any amendment or reports filed for the purpose of updating such description.
35


All future documents that we filecontrary) made with the SEC pursuant to SectionSections 13(a), 13(c), 14 or 15(d) of the Exchange Act, including those made after the date of the initial filing of the registration statement of which this prospectus is a part and prior to effectiveness of such registration statement, until we file a post-effective amendment that indicates the termination or completionof the offering of the securities made by this prospectus, which will become a part of this offering of common stock shallprospectus from the date that such documents are filed with the SEC. Information in such future filings updates and supplements the information provided in this prospectus. Any statements in any such future filings will automatically be deemed to modify and supersede any information in any document we previously filed with the SEC that is incorporated or deemed to be incorporated herein by reference in this prospectus and to be a part of it from the filing dates of such documents (except in each case the information contained in such documents to the extent “furnished” and not “filed”). Certainthat statements in and portions of this prospectus update andthe later-filed document modify or replace information in the above listed documents incorporated by reference. Likewise, statements in or portions of a future document incorporated by reference in this prospectus may update and replace statements in and portions of this prospectus or the above listed documents. To the extent there is a conflict between the information contained in this prospectus, on the one hand, and the information contained in any document incorporated by reference into this prospectus that was filed with the SEC before the date of this prospectus, on the other hand, you should rely on the information in this prospectus. If any statement in one of these documents is inconsistent with a statement in another document having a later date, the statement in the document having the later date modifies or supersedes thesuch earlier statement.

statements. We will providefurnish without charge to each person, including any beneficial owner, to whom a copy of this prospectus is delivered, upon written or oral request, of any such person, a copy of any or all of the documents incorporated by reference into this prospectus but not delivered with the prospectus, including exhibits that are specifically incorporated herein by reference. Requestsreference into such documents. You should be directeddirect any requests for documents to:

Atrinsic,

Protagenic Therapeutics, Inc.

469 7th

149 Fifth Avenue 10th Floor

New York, NY 10018New York 10010

212-994-8200

Attention: Chief Financial Officer

17
Attn: Investor Relations

PROSPECTUS

7,221,607 Shares of Common Stock Offered by Selling Stockholders

18
(212) 716-1977


36


PART

Part II

INFORMATION NOT REQUIRED IN PROSPECTUS

Information not required in prospectus

ITEM 14.  

Item 13.Other Expenses of Issuance and Distribution.

Distribution

The following table itemizes thesets forth our costs and expenses incurred by the Registrant in connection with the offering. registration of our securities as described in this registration statement.

  AMOUNT 
SEC registration fee $1,520.60 
Legal fees and expenses $20,000 
Accounting fees and expenses $10,000 
Miscellaneous expenses $1000 
Total $32,520.60 

All the amounts shown are estimates, exceptother than the SecuritiesSEC’s registration fee.

We are paying all expenses of the offering listed above. No portion of these expenses will be borne by the selling stockholders.

The selling stockholders, however, will pay all underwriting discounts and Exchange Commission registration fee.

  Amount 
Registration fee – Securities and Exchange Commission $2,367 
Legal fees and expenses  150,000 
Accounting fees and expenses  75,000 
Miscellaneous expenses  5,000 
Total $232,367 
selling commissions, if any.

ITEM 15.  

Item 14.Indemnification of Directors and Officers.

TheOfficers

We are incorporated under the laws of the state of Delaware. Section 145 of the Delaware General Corporation Law and certain provisionsprovides that a Delaware corporation may indemnify any persons who are, or are threatened to be made, parties to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of our certificate of incorporation and bylaws under certain circumstances provide for indemnification of our officers, directors and controlling persons against liabilities which they may incur in such capacities. A summarycorporation), by reason of the circumstances in whichfact that such indemnification is provided for is contained herein, but this description is qualified in its entirety by reference to our certificate of incorporation, bylaws and to the statutory provisions.

In general, anyperson was an officer, director, employee or agent of such corporation, or is or was serving at the request of such person as an officer, director, employee or agent of another corporation or enterprise. The indemnity may be indemnified againstinclude expenses (including attorneys’ fees), judgments, fines settlements or judgments arisingand amounts paid in settlement actually and reasonably incurred by such person in connection with a legalsuch action, suit or proceeding, to whichprovided that such person is a party, if that person's actions wereacted in good faith wereand in a manner he or she reasonably believed to be in or not opposed to ourthe corporation’s best interests and, with respect to any criminal action or proceeding, such person had no reasonable cause to believe theirthat his or her conduct was illegal. A Delaware corporation may indemnify any persons who are, or are threatened to be made, a party to any threatened, pending or completed action or suit by or in the right of the corporation by reason of the fact that such person was a director, officer, employee or agent of such corporation, or is or was serving at the request of such corporation as a director, officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit provided such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the corporation’s best interests except that no indemnification is permitted without judicial approval if the officer or director is adjudged to be liable to the corporation. Where an officer or director is successful on the merits or otherwise in the defense of any action referred to above, the corporation must indemnify him or her against the expenses that such officer or director has actually and reasonably incurred. Our charter and bylaws provide for the indemnification of our directors and officers to the fullest extent permitted under the Delaware General Corporation Law.

Section 102(b)(7) of the Delaware General Corporation Law permits a corporation to provide in its certificate of incorporation that a director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duties as a director, except for liability for:

any breach of the director’s duty of loyalty to the corporation or its stockholders;
any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
any act related to unlawful stock repurchases, redemptions or other distributions or payment of dividends; or
any transaction from which the director derived an improper personal benefit.

19

These limitations of liability do not affect the availability of equitable remedies such as injunctive relief or rescission. Our charter also authorizes us to indemnify our officers, directors and other agents to the fullest extent permitted under Delaware law.

As permitted by Section 145 of the Delaware General Corporation Law, our bylaws provide that:

we may indemnify our directors, officers and employees to the fullest extent permitted by the Delaware General Corporation Law, subject to limited exceptions;
we may advance expenses to our directors, officers and employees in connection with a legal proceeding to the fullest extent permitted by the Delaware General Corporation Law, subject to limited exceptions; and
the rights provided in our bylaws are not exclusive.

Section 174 of the Delaware General Corporation Law provides, among other things, that a director who willfully or negligently approves of an unlawful payment of dividends or an unlawful stock purchase or redemption may be held liable for such actions. A director who was either absent when the unlawful actions were unlawful. Unlessapproved, or dissented at the time, may avoid liability by causing his or her dissent to such person is successful uponactions to be entered in the merits in such an action, indemnification may be awarded only after a determination by independent decisionbooks containing minutes of the meetings of the board of directors at the time such action occurred or a committee thereof, by legal counsel, or by a voteimmediately after such absent director receives notice of the unlawful acts.

Our Third Amended and Restated Certificate of Incorporation provides that no director shall be liable to us or our stockholders thatfor monetary damages for breach of fiduciary duty as a director to the applicable standard of conduct was metfullest extent permitted by the personDGCL.

We have entered into Indemnification Agreements with the each of our directors and executive officers. Pursuant to our agreements, we will be indemnified.

The circumstances under which indemnification is granted in connection with an action brought onobligated, to the extent permitted by applicable law, to indemnify our behalf is generally the same as those set forth above; however, with respect to such actions, indemnification is granted only with respect todirectors and officers against all expenses, actuallyjudgments, fines and penalties incurred in connection with the defense or settlement of any actions brought against them by reason of the action. In such actions, unless the court determines otherwise, the personfact that they were our directors or officers or assumed certain responsibilities at our direction.

We also have purchased directors and officer’s liability insurance in order to limit our exposure to liability of indemnification of directors and officers.

The form of Underwriting Agreement, to be indemnified must have actedfiled as Exhibit 1.1 hereto, provides for indemnification by the underwriters of us and our officers who sign this Registration Statement and directors for specified liabilities, including matters arising under the Securities Act.

20

Item 15. Recent Sales of Unregistered Securities.

Original Issuances of Stock and Warrants

2019-2020 Convertible Note Offering

From November 21, 2019 through July 8, 2020, Protagenic Therapeutics, Inc. (the “Company”) entered into a Convertible Note Purchase Agreement (“Purchase Agreement”) with accredited investors (the “Investors”), pursuant to which the Company issued and sold unsecured convertible promissory notes (collectively, the “Notes”) to the Investors in good faiththe aggregate principal amount of $1,570,000, as reported in Current Reports on Form 8-K filed on November 21, 2019, December 4, 2019, December 23, 2019, January 29, 2020, March 3, 2020, May 14, 2020, and July 8, 2020.

On August 11, 2020, the Company notified investors in a manner believedconference call that it was re-opening the convertible note financing, with identical terms to havethe previous round, except for the closing date, which has now been set at Friday, August 21st, at 5:00 pm.

On August 28, 2020, the “Company” entered into a Convertible Note Purchase Agreement with certain accredited investors, pursuant to which the Company issued and sold unsecured convertible promissory notes to the Investors in our bestthe aggregate principal amount of $427,500.

For both sets of Notes, the Notes will be due on November 6, 2023 (the “Maturity Date”) and accrue simple interest at an annual rate of 6% on the aggregate unconverted and haveoutstanding principal amount, payable annually, beginning October 31, 2020. The Company will pay (a “PIK Payment”) the interest due by adding such interest (including interest at the Default Rate, as defined below, if any) to the then-outstanding principal amount of the Notes on each interest payment date and on the Maturity Date. Each PIK Payment will be preceded by written notice from the Company to each holder of the Notes setting forth in reasonable detail the amount of such PIK Payment and the principal amount of the Notes following such PIK Payment. The Notes will bear interest at the rate of 12% per year (the “Default Rate”) following a Default (as defined below).

Holders may convert their Notes (including accrued interest) at their option, in whole or in part, at any time prior to the Maturity Date, at a conversion price (the “Conversion Price”) of $1.25 per share of the Company’s common stock, par value $0.0001 per share. The Conversion Price is subject to adjustment for any stock dividend, stock split, combination or other similar recapitalization event. On the Maturity Date, the Company is required to repay the Notes (including accrued interest) in their entirety in cash or, at its option, in shares of common stock at the Conversion Price.

The Company may redeem for cash or shares of common stock all or any portion of the Notes, at its option, on or after November 5, 2021 if the last reported sale price of its common stock has been at least 120% of the Conversion Price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which it provides notice of redemption. The redemption will be effected at a redemption price equal to 100% of the outstanding principal amount of the Notes to be redeemed, plus accrued and unpaid interest up to, but excluding, the redemption date. Any such redemption must be applied ratably among all Convertible Notes in proportion to their respective outstanding principal balances, plus accrued and unpaid interest. Other than pursuant to this redemption right, the Company may not pre-pay the Notes.

Securities Act Exemptions

We deemed the transactions described above were exempt from registration under the Securities Act in reliance on Section 4(a)(2) of the Securities Act, including Regulation D and Rule 506 promulgated thereunder, relative to transactions by an issuer not involving a public offering. All purchasers of securities in transactions exempt from registration pursuant to Regulation D represented to us that they were accredited investors and were acquiring the shares for investment purposes only and not with a view to, or for sale in connection with, any distribution thereof and that they could bear the risks of the investment and could hold the securities for an indefinite period of time. The purchasers received written disclosures that the securities had not been adjudged liable toregistered under the corporation.

Indemnification may alsoSecurities Act and that any resale must be granted pursuant to the terms of agreements which we have entered into and which may be entered into in the future ormade pursuant to a voteregistration statement or an available exemption from such registration.

All certificates representing the securities issued in the transactions described in this Item 15 included appropriate legends setting forth that the securities had not been offered or sold pursuant to a registration statement and describing the applicable restrictions on transfer of stockholders or directors. The statutory provision cited above also grants the power to us to purchase and maintain insurance which protects our officers and directors against any liabilities incurredsecurities. There were no underwriters employed in connection with their service in such a position, and such a policy may be obtained by us.

A stockholder's investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers as required by these indemnification provisions. At present, there is no pending litigation or proceeding involving any of our directors, officers or employees regarding which indemnification by us is sought, nor are we aware of any threatened litigation that may resultthe transactions set forth in claims for indemnification.

this Item 15.

21
II-1



ITEM

Item 16.  Exhibits.

Exhibits

The following is a list of all exhibits are filed herewith:

as a part of this registration statement on Form S-3, including those incorporated herein by reference.

Exhibit
Number
No.
 Exhibit TitleDocument
   
4.11.1* Form of Senior SecuredUnderwriting Agreement.
3.1†Third Amended and Restated Certificate of Incorporation of Protagenic Therapeutics, Inc. (Incorporated by reference to Exhibit 3.1 to Company’s Current Report on Form 8-K, as filed with the SEC on June 20, 2016).
3.2†Certificate of Designations, Powers, Preferences and Other Rights of Preferred Stock and Qualifications, Limitations and Restrictions Thereof of Series B Convertible Note (1)Preferred Stock of Atrinsic, Inc. (Incorporated by reference to Exhibit 3.1 to Company’s Current Report on Form 8-K, as filed with the SEC on February 5, 2016).
3.3†Second Amended and Restated Bylaws Protagenic Therapeutics, Inc., (Incorporated by reference to Exhibit 3.1 to Company’s Current Report on Form 8-K, as filed with the SEC on June 1, 2018).
5.1†Opinion of Duane Morris LLP. (Incorporated by reference to Exhibit 5.1 to Company’s Registration Statement on Form S-3, as filed with the SEC on August 13, 2021)
21.1†Subsidiaries (Incorporated by reference to Exhibit 21.1 to Company’s Annual Report on Form 10-K, as filed with the SEC on March 24, 2021)
23.1**Consent of MaloneBailey, LLP, Independent Registered Public Accounting Firm.
23.2†Consent of Duane Morris LLP (included in Exhibit 5.1).
24.1†Powers of Attorney

* To the extent applicable, to be filed by a post-effective amendment or as an exhibit to a document filed under the Exchange Act and incorporated by reference herein.

** Filed herewith

† Previously filed.

Item 17.Undertakings

a.The undersigned Registrant hereby undertakes:

1.To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

i.To include any prospectus required by Section 10(a)(3) of the Securities Act;
   
4.2ii.FormTo reflect in the prospectus any facts or events arising after the effective date of Series A Warrant (1)the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement.
   
4.3iii.FormTo include any material information with respect to the plan of Series B Warrant (1)
4.4Form of Series C Warrant (1)
4.5Securities Purchase Agreement by and among Atrinsic, Inc. anddistribution not previously disclosed in the Buyers set forth on the signature pages thereto. (2)
4.6Form of Registration Rights Agreement by and among Atrinsic, Inc. and the Buyers set forth on the signature pages thereto. (1)
5.1Opinion of Stubbs, Alderton and Markiles, LLP.
23.1Consent of Stubbs, Alderton & Markiles, LLP (included in Exhibit 5.1).
23.2Consent of KPMG LLP.
24.1Power of Attorney (3)

(1)Incorporated by reference to our Current Report on Form 8-K filed on June 1, 2011.
(2)Incorporated by reference to our Registration Statement on Form S-3/A filed on September 1, 2011.or any material change to such information in the registration statement;
(3)Incorporated by reference to our Registration Statement on Form S-3 filed on July 1, 2011.
ITEM 17.  Undertakings.
(a) The undersigned registrant hereby undertakes:

1. To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

(i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Securities and Exchange Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement.

(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.

provided,Provided however, that paragraphs (a)(1)(i), (a)(1)(ii), and (a)(1)(iii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the CommissionSEC by the registrantRegistrant pursuant to Sectionsection 13 or Sectionsection 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.


2.That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

22

3.To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
4.That, for the purpose of determining liability under the Securities Act to any purchaser:

i.Each prospectus filed by the Registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and

ii.Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by section 10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; provided, however, that no statement made in a registration statement or prospectus that is part of the Registration Statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the Registration Statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.

5.That, for the purpose of determining liability of the Registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned Registrant undertakes that in a primary offering of securities of the undersigned Registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

i.Any preliminary prospectus or prospectus of the undersigned Registrant relating to the offering required to be filed pursuant to Rule 424;
ii.Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned Registrant or used or referred to by the undersigned Registrant;
iii.The portion of any other free writing prospectus relating to the offering containing material information about the undersigned Registrant or its securities provided by or on behalf of the undersigned Registrant; and
iv.Any other communication that is an offer in the offering made by the undersigned Registrant to the purchaser.

b.The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to section 13(a) or section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
c.The undersigned registrant hereby undertakes to supplement the prospectus, after the expiration of the subscription period, to set forth the results of the subscription offer, the transactions by the underwriters during the subscription period, the amount of unsubscribed securities to be purchased by the underwriters, and the terms of any subsequent reoffering thereof. If any public offering by the underwriters is to be made on terms differing from those set forth on the cover page of the prospectus, a post-effective amendment will be filed to set forth the terms of such offering.

d.Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

II-2
23


2. That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide SIGNATURESoffering thereof.


3. To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

4. That, for purposes of determining liability under the Securities Act of 1933 to any purchaser:

(i) Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and

(ii) Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.

5.           (ii) Each prospectus filed pursuant to Rule 424(b) as part of this registration statement, shall be deemed to be part of and included in this registration statement as of the date it is first used after effectiveness; provided, however, that no statement made in this registration statement or prospectus that is part of this registration statement or made in a document incorporated or deemed incorporated by reference into this registration statement or prospectus that is part of this registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in this registration statement or prospectus that was part of this registration statement or made in any such document immediately prior to such date of first use.

(b)          The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(c)          Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

II-3


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3/AS-3 and has duly caused this registration statementRegistration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on September 29, 2011.


10, 2021.

 Atrinsic, Inc.PROTAGENIC THERAPEUTICS, INC.
  
 By:/s/ Stuart GoldfarbGaro H. Armen
Name:Garo H. Armen
Title:Chairman (Principal Executive
  Stuart Goldfarb
Chief Executive Officer
(Principal Executive and Duly Authorized Officer)

24

Pursuant to the requirements of the Securities Act of 1933, this Registration Statementregistration statement has been signed by the following persons in the capacities and on the dates stated.

indicated.

NameSignature Title Date
/s/ Garo H. Armen

Garo H. Armen

Director and Chairman of the Board (Principal Executive Officer)September 10,2021
/s/ Alexander K. Arrow

Alexander K. Arrow

Chief Financial Officer (Principal Financial Officer)September 10, 2021
     
/s/ Stuart GoldfarbPresident and Chief ExecutiveSeptember 29, 2011
Stuart Goldfarb
Officer and Director
(Principal Executive Officer)
Robert B. Stein *
  

Robert B. Stein

Director and Chief Medical OfficerSeptember 10,2021
     
/s/ Nathan FongChief Financial OfficerSeptember 29, 2011
Nathan Fong
(Principal Financial Officer and
Principal Accounting Officer)
Khalil Barrage *
  

Khalil Barrage

DirectorSeptember 10,2021
     
/s/ Brian Corvese*

Brian Corvese

 Director September 29, 2011
Ray Musci10,2021
     
/s/ Jennifer Buell *

Jennifer Buell

 Director September 29, 2011
Lawrence Burstein10,2021
     
/s/ Joshua Silverman*

Joshua Silverman

 Director September 29, 201110,2021

Mark Dyne* By:/s/ Alexander K. Arrow 
 Alexander K. Arrow 
*DirectorSeptember 29, 2011
Jerome A. ChazenAttorney-in-fact 

*   By: /s/ Stuart Goldfarb
Stuart Goldfarb, as attorney-in-fact25

II-4


EXHIBIT INDEX
Exhibit
Number
Exhibit Title
4.1Form of Senior Secured Convertible Note (1)
4.2Form of Series A Warrant (1)
4.3Form of Series B Warrant (1)
4.4Form of Series C Warrant (1)
4.5Securities Purchase Agreement by and among Atrinsic, Inc. and the Buyers set forth on the signature pages thereto. (2)
4.6Form of Registration Rights Agreement by and among Atrinsic, Inc. and the Buyers set forth on the signature pages thereto. (1)
5.1Opinion of Stubbs, Alderton and Markiles, LLP.
23.1Consent of Stubbs, Alderton & Markiles, LLP (included in Exhibit 5.1).
23.2Consent of KPMG LLP.
24.1Power of Attorney (3)

(1)Incorporated by reference to our Current Report on Form 8-K filed on June 1, 2011.
(2)Incorporated by reference to our Registration Statement on Form S-3/A filed on September 1, 2011.
(3)Incorporated by reference to our Registration Statement on Form S-3 filed on July 1, 2011.

II-5